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ABSTRACT 
The essential omega 3 (n-3) fatty acid alpha-linoleic acid (ALA) and the n-3 fatty 
acids eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA), and docosahexaenoic 
acid (DHA) are important structural components of cell membranes. During pregnancy a 
steady supply of n-3 fatty acids is required to support positive fetal development (1-4) and 
maternal health (5-9).  Over the past decade, extensive clinical research has focused on the 
role of DHA during pregnancy because it is incorporated into fetal brain grey matter and 
retina cell membranes more than any other n-3 fatty acid (4).  Previous clinical research 
shows DHA intake during pregnancy supports positive fetal visual acuity and motor skills. No 
known studies have the primary objective of determining the association of the food 
frequency questionnaire (FFQ) estimated intakes with some other dietary assessment tool 
and blood biomarkers for total and individual n-3 fatty acids in pregnant women from non-
coastal communities.  The objective of the present study was 1) to determine the ability of 
the semi-quantitative FFQ to estimate intake of total n-3, ALA, EPA, DPA, and DHA and 2) 
to examine the relationship between the semi-quantitative FFQ and weighed 3-day diet 
record (3dDR) intake with plasma phospholipids (PLs) and RBC esterified fatty acids 
(phoshatidylethanolamine (PE) and phosphatidylcholine (PC)) for total and individual n-3 
fatty acids (ALA, EPA, DPA, and DHA) in pregnant women from two non-coastal 
communities.  It was hypothesized that 1) a significant association between the FFQ and 
3dDR for total and individual n-3 fatty acid estimated intakes would be found and 2) total 
and individual n-3 fatty acid intakes estimated from the FFQ would show strong correlations 
with RBC PE and PC total and individual n-3 fatty acid compositions.  Intake of total and 
individual n-3 fatty acids were estimated using the FFQ and weighed 3dDR in 136 healthy, 
pregnant women between 15-34 weeks gestation during a prospective observational study. 
A subset of subjects of64 pregnant women (25-31 weeks of gestation) were used to 
vi 
determine the associations between the FFQ and weighed 3dDR and blood biomarkers.  
Spearman’s correlations indicated a significant positive association between the FFQ and 
weighed 3dDR for intake of total n-3 (rho=0.98), ALA (rho=0.27), EPA (r=0.56) and DHA 
(r=0.66) (P<0.01).  Spearman’s correlations coefficients between the intakes estimated from 
the FFQ and plasma PL for EPA and DHA (rho=0.33 and rho=0.46, respectively), and RBC 
PE and PC for total n-3 (rho=0.39 and rho=0.27, respectively), EPA, (rho=0.45 and 
rho=0.36, respectively) and DHA (rho=0.56 and rho=0.47, respectively) were significant.   
DHA intake obtained from the 3dDR exhibited a significant positive association for plasma 
PL (rho=0.34) and RBC PE and PC (rho=0.40 and rho=0.42, respectively).  The 3dDR DPA 
estimated intake was not associated with blood biomarkers.  In conclusion, the semi-
quantitative FFQ is an appropriate dietary assessment tool to estimate intake of total n-3, 
ALA, EPA and DHA and correlates well with the weighed 3dDR and blood biomarkers.      
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CHAPTER 1:  General Introduction 
Consumption of omega 3 (n-3) fatty acids during gestation has been shown to 
benefit mother and baby.  The essential n-3 fatty acid alpha-linolenic acid (ALA) and the n-3 
fatty acids eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA), and 
docosahexaenoic acid (DHA) support maternal (1-5) and fetal health (6-9). DHA is a major 
component of brain grey matter and retinal phospholipids (6).  Clinical research shows DHA 
intake during pregnancy supports positive fetal visual acuity and motor skills (6-9). The 
Adequate Intake (AI) for ALA for pregnant women is 1.4 g/d and is routinely met in the 
American diet (10).  Clinical research shows DHA intake during pregnancy supports positive 
fetal visual acuity and motor skills development (6-9). Maternal intake of at least 200 mg 
DHA per day throughout gestation is recommended to support a healthy pregnancy, to 
prevent maternal depletion of DHA and to meet the increased fetal demands of 67 mg DHA 
per day during the third trimester, a period of rapid fetal growth (11-13).  At this time there 
are no dietary recommendations for EPA and DPA intake during pregnancy.  Common 
sources of ALA include soybean, canola oil, and flaxseed oil (12).  Dietary sources of DHA 
are fatty fish, seafood, meat, and eggs (13); EPA and DPA are routinely found in the same 
dietary sources as DHA (14-15).  Fortified foods and supplements are also consumable 
sources of ALA, EPA and DHA.         
Studies reporting dietary intake of n-3 fatty acids in pregnant women are limited (15-
20).  Accurate assessment of n-3 fatty acid intake during pregnancy may be useful in clinical 
settings and during nutrition related research.  Possible dietary assessment tools include the 
weighed diet record, 24-hour recall, and the food frequency questionnaire (FFQ).  The 
weighed diet record and 24-hour recall measure mean usual intake (i.e. intake of nutrients 
consumed nearly every day) for a group (21).  Unless these tools are administered in 
multiple instances, they do not quantify episodic intake or non-typically consumed nutrients 
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such as n-3 fatty acids (22).  The weighed diet record and 24-hour recall have been used as 
reference tools when developing an FFQ to assess fatty acid intake in non-pregnant 
individuals (23-28).  The weighed diet record has been more commonly used as a reference 
method than the 24 hour recall to assess dietary fatty acid intake in non-pregnant individuals 
(23-27).  The semi-quantitative FFQ is cost effective and has been used to measures 
episodic intake from 30 days to 5 years in a wide variety of populations (29-31).  The FFQ 
has been used to measure n-3 fatty acid intake in non-pregnant individuals (23-28).  No 
known studies exist that have the primary objective of determining the association of the 
FFQ with some other dietary assessment tool when intake of ALA, EPA, DPA, and DHA is 
measured in healthy pregnant women.  The semi-quantitative FFQ may be the most suitable 
dietary assessment tool to measure n-3 fatty acid intake in pregnant women because EPA 
and DHA are episodically consume nutrients.  Each of these tools has strengths and 
limitations that are discussed thoroughly in the following literature review.   
Dietary assessment tools have also shown agreement with biological measurements 
(i.e. adipose and blood biomarkers) which measure nutrient status (33-36).  Biological 
measurements provide a relatively accurate assessment of fatty acid status because they 
are objective, do not rely on memory or compliance of the participant, and can be used to 
assess short and long term status (33-36).  Maternal fatty acid status has been previously 
measured using red blood cell (RBC) esterified fatty acids (i.e. phoshatidylethanolamine 
(PE) and phosphatidylcholine (PC)) and plasma phospholipids (PLs) (33).  Both RBC and 
plasma fatty acid fractions have shown positive correlations with n-3 fatty acid intake 
measured by an FFQ in non-pregnant individuals (26-27).  Fatty acid compositions of RBC 
and plasma fractions may be useful in determining the association between maternal fatty 
acid status and dietary intake of fatty acids during pregnancy. 
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When validating a dietary assessment tool to assess the intake of a particular 
nutrient for specific population it is necessary to have a dietary reference method and to 
know the strengths and limitations both tools.  Additionally, it is beneficial to compare both 
dietary assessment tools to a more objective method like biological measurements.  
I. Specific Aims (Figure 1) 
Specific Aim #1:  To characterize a semi-quantitative FFQ and weighed 3dDR using 
descriptive statistics for their ability to estimate total n-3 fatty acids and individual n-3 fatty 
acids, including DHA, ALA, EPA, and DPA.  
Specific Aim #2:  To determine the association between the FFQ and the 3dDR 
when intake of total n-3 and individual n-3 fatty acids (ALA, EPA, DPA, and DHA) are 
estimated in women during the 2nd and 3rd trimester of pregnancy. 
Null Hypothesis:  The total n-3 and individual n-3 fatty acid (ALA, EPA, DPA and 
DHA) intake estimated via the FFQ is not associated with the total n-3 and 
individual n-3 fatty acid (DHA, ALA, EPA, and DPA) intake collected via the 
3dDR in women during the 2nd and 3rd trimester of pregnancy. 
Alternative Hypothesis:  The total n-3 and individual n-3 fatty acid (ALA, EPA, DPA 
and DHA) intake estimated via the FFQ is associated with the total n-3 and 
individual n-3 fatty acid (DHA, ALA, EPA, and DPA) intake collected via the 
3dDR in 3dDR in women during the 2nd and 3rd trimester of pregnancy. 
Specific Aim #3:  To determine the association between the total n-3 and individual 
n-3 fatty acid (ALA, EPA, DPA and DHA) intakes estimated via the FFQ and 3dDR with the 
total n-3 and individual n-3 fatty acid (ALA, EPA, DPA and DHA) status determined by blood 
biomarkers (RBC and plasma) in women during the 2nd and 3rd trimester of pregnancy. 
Null Hypothesis 1:  The total n-3 and individual n-3 fatty acid (ALA, EPA, DPA and 
DHA) intake estimated via the FFQ is not associated with total n-3 and 
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individual n-3 fatty acid (ALA, EPA, DPA and DHA) status measured by the 
analysis of RBC biomarkers (PE, PC) in women during the 2nd and 3rd 
trimester of pregnancy. 
Alternative Hypothesis 1:  The total n-3 and individual n-3 fatty acid (ALA, EPA, DPA 
and DHA intake estimated via the FFQ is associated with total n-3 and 
individual n-3 fatty acid (ALA, EPA, DPA and DHA) status measured by the 
analysis of RBC biomarkers (PE, PC)  of in women during the 2nd and 3rd 
trimester of pregnancy. 
Null Hypothesis 2:  The total n-3 and individual n-3 fatty acid (ALA, EPA, DPA, and 
DHA) intake estimated via the FFQ is not associated with total n-3 and 
individual n-3 fatty acid (ALA, EPA, DPA and DHA) status measured by the 
analysis of plasma blood biomarker (PL) of of in women during the 2nd and 3rd 
trimester of pregnancy. 
Alternative Hypothesis 2:  The total n-3 and individual n-3 fatty acid (ALA, EPA, DPA 
and DHA) intake estimated via the FFQ is associated with total n-3 and 
individual n-3 fatty acid (ALA, EPA, DPA and DHA) status measured by the 
analysis of plasma blood biomarker (PL) of in women during the 2nd and 3rd 
trimester of pregnancy. 
Null Hypothesis 3:  The total n-3 and individual n-3 fatty acid (ALA, EPA, DPA and 
DHA) intake estimated via the 3dDR is not associated with total n-3 and 
individual n-3 fatty acid (ALA, EPA, DPA and DHA) status measured by the 
analysis of RBC biomarkers (PE, PC) of in women during the 2nd and 3rd 
trimester of pregnancy. 
Alternative Hypothesis 3:  The total n-3 and individual n-3 fatty acid (ALA, EPA, DPA 
and DHA) intake estimated via the 3dDR is associated with total n-3 and 
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individual n-3 fatty acid (ALA, EPA, DPA and DHA) status measured by the 
analysis of RBC biomarkers (PE, PC) of in women during the 2nd and 3rd 
trimester of pregnancy. 
Null Hypothesis 4:  The total n-3 and individual n-3 fatty acid (ALA, EPA, DPA and 
DHA) intake estimated via the 3dDR is not associated with total n-3 and 
individual n-3 fatty acid (ALA, EPA, DPA and DHA) status measured by the 
analysis of plasma blood biomarker (PL) of in women during the 2nd and 3rd 
trimester of pregnancy. 
Alternative Hypothesis 4:  The total n-3 and individual n-3 fatty acid (ALA, EPA, DPA 
and DHA) intake estimated via the 3dDR  is associated with total n-3 and 
individual n-3 fatty acid (ALA, EPA, DPA and DHA) status measured by the 
analysis of plasma blood biomarker (PL) of in women during the 2nd and 3rd 
trimester of pregnancy. 
 
      
 
   
 
 
 
 
 
 
 
Figure 1.  Specific Aims Flow Chart.   
Specific Aim 1:  Characterize FFQ and 
3dDR ability to assess intake 
Specific Aim 2:  To test the ability of the 
FFQ to predict 3dDR 
Specific Aim 3:  Compare dietary intake to blood 
biomarkers (RBC and plasma) 
3dDR 
vs 
plasma 
(PL) 
3dDR 
vs 
RBC 
(PE, PC) 
FFQ 
vs 
plasma 
(PL) 
 
FFQ 
vs 
RBC 
(PE, PC) 
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Thesis Organization 
 This thesis begins with a general introduction and specific aims.  The literature 
review focuses on omega 3 fatty acids, dietary assessment tools, and biomarker 
assessment tools.   Third, the research methods are provided.   The papers Dietary intake 
of total and individual n-3 fatty acids by pregnant women:  associations between the 
semi-quantitative food frequency questionnaire and weighed diet record and 
Validation of a semi-quantitative food frequency questionnaire with blood biomarkers 
in pregnant women for total and individual n-3 fatty acids will be submitted to the 
Journal of American Dietetic Association.  A general conclusion is included following the 
papers. 
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CHAPTER 2:  Literature Review 
I. Omega-3 Fatty Acids 
a. Stereochemistry and nomenclature (37-38) 
Fatty acids are a class of lipids.  Stereospecific numbering (sn) is used to describe 
fatty acid molecules and can easily be explained by using the triacylglycerol (TAG) form of a 
fatty acid as an example. Triacylglycerols are composed of a three carbon glycerol 
backbone.  Drawn in a Fischer Project, the first carbon that appears on the top of the 
glycerol backbone and that is bound to a hydroxyl group is labeled sn-1.  The second 
carbon, located below the sn-1 carbon and typically bound to a carboxyl group, is labeled 
sn-2; the third carbon, labeled sn-3, is also bound to a hydroxyl group.  More vaguely 
described, a fatty acid is of a hydrophilic carboxylic group followed by a series of methylene 
linked groups which form a hydrophobic tail.   
Fatty acids are classified by the number of carbons within a hydrocarbon chain.  
Short chain fatty acids contain between 3 to 7 carbon atoms while medium chain fatty acids 
contain 8 to 13 carbon atoms; long chain fatty acids contain 14 to 22 carbon atoms and very 
long chain fatty acids contain more than 22 carbons.  Most naturally occurring fatty acids are 
in the cis-configuration (Figure 2).  Nomenclature of fatty acids is determined by the length 
of the hydrocarbon chain and the number and location of double bonds with the chain.  
There are various methods for naming fatty acids.    Systematic naming of fatty acids is 
determined by the number of carbon atoms the molecule contains, the location of the first 
double bond from the carboxylic group of the fatty acid and the location of the remaining 
carbon-carbon double bonds with in the hydrocarbon chain.   For example, the systematic 
name of DHA is cis-4, cis-7, cis-10, cis-13, cis-16, cis-19 docosahexaenoic acid. As a result 
of this lengthy and cumbersome name, fatty acids are often referred to in shorthand or the 
“n minus” naming system.  Using this identification method, the first number listed defines 
 the number of carbons within the chain, the second number indicates the number of double 
bonds and “n minus” indicates the location of the double bond closest to the methyl end of 
the molecule.  Using DHA as an example again, it has 22 carbons within its hydrocarbon 
chain and 6 double bonds with the first double bond located at the omega 3 (n
22:6n-3. 
 
Figure 2. Structure of docosahexae
b. Digestion, absorption, metabolism, and compartmentalization of fatty acids
Dietary fatty acids include non
phospholipids (PLs), and cholesterol
the activation of lingual and gastric lipases.  It is continued in the small intestine via 
phospholipase A2, colipase, cholesterol esterase, and pancreatic lipase.  The end product
of the digestive process are lipid
diacylglycerides, and TAGs.   
Lipid moieties are absorbed into the enterocyte
enterocyte, dietary fatty acids
nascent chylomicrons.   Nascent chylomicrons are immature or functionally incomplete 
chylomicrons composed of TAG, PL
apolipoprotein 48 (apo 48).  Apolipoproteins are fat binding proteins. 
When the chylomicron is
circulation it becomes 'mature' or a lipoprotein through the addition of apo C and apo E 
proteins (37).  It is the plasma PL found
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noic acid (DHA). 
-esterified fatty acids (NEFA), TAG, plasma 
.  Digestion of dietary fat begins in the stomach 
 moieties such as NEFAs, monoaclyglycerides, 
 
 of the small intestine.  Within the 
 are emulsified by bile salts to form micelles which then form 
, cholesterol and apolipoproteins specifically 
 
 released from the enterocyte into portal and then systemic 
 in the lipoprotein molecule that is measured to 
-3) position:  
 
 
through 
s 
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assess short term fatty acid status like DHA.   Typically, DHA is measured in the sn-2 
position of plasma PL of circulating lipoproteins (Figure 3).      
As the apolipoproteins of the lipoprotein come in contact with lipoprotein lipase of 
extrahepatic tissues (adipose and muscle), the TAG rich particle shrinks in size as it donates 
monounsaturated fatty acids, polyunsaturated fatty acids, long chain polyunsaturated fatty 
acid (LCPUFAs), saturated fats, and trans fats to the tissues (36).  Once delivered to the cell 
these lipids play a variety of functions (e.g. cell signaling and membrane structure).  Unlike 
extrahepatic tissues, RBC does not use lipoprotein lipase to acquire fatty acids.  Albumin 
transports plasma fatty acids into RBC membranes via acylation-deacylation.   Red blood 
cell membranes have a mosaic bilayer membrane made of cholesterol, protein, and 
phospholipids (glycerophospholipids and sphingolipids) (36).  Sphingolipids are comprised 
of a de novo synthesized sphingoid base backbone amide linked to a long chain fatty acid 
(36).  Sphingomyelins are the sphingolipids typically found in the outer membrane of the 
RBC.   Glycerophospholipids are comprised of carbon backbone made of one to three fatty 
acid esters.  There are classified into two groups-phosphoglycerides and glycosylglycerides 
(36).  Two phosphoglycerides (i.e. phoshatidylethanolamine (PE) and phosphatidylcholine 
(PC)) are commonly found within the RBC lipid bilayer and are acyl-linked at sn2 position 
fatty acid glycerol backbone.  Within the RBC lipid bilayer PC favors the outer membrane 
and PE favors the inner membrane (37). While most fatty acids transferred into the RBC 
membrane are preferentially acyl-linked to PE, both phosphoglycerides are used to quantify 
fatty acid status when using the RBC (Figure 3) (38).   
 
 Figure 3.  Structures of phoshatidylethanolamine (
phospholipids (PLs). 
 
 
c. Omega 6 and omega 3 fatty acid metabolism
 
The two essential fatty acids (EFAs) linoleic acid (LA) and 
cannot be synthesized by human tissue and must be ob
development of specialized cells throughout the body (
the delta (∆) 12- and ∆ 16- desaturase enzymes needed to introduce carbon
bonds between the tenth carbon and the methyl end of the fatty acid chain of stearic acid to 
endogenously form LA or ALA (3
Linoleic acid, an omega 
linolenic acid (DGLA).  It forms DGLA through a series of enzymatic reactions involving delta 
(∆) 6-desaturase and elongase (Figure 4).  The function of a desaturase enzyme is to form 
10 
PE) and phosphatidylcholine (PC
 
alpha-linolenic acid (
tained from the diet for normal 
40).  This is because 
7-38).   
6 (n-6) fatty acid, is the metabolic precursor to dihomo
 
) and 
ALA) 
humans lack 
-carbon double 
-y-
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carbon-carbon double bonds and the function of an elongase is to lengthen fatty acid chains 
by the addition of two carbon units.   Dihomo-y-linolenic acid is further desaturated to 
arachidonic acid (ARA) via ∆ 5-desaturase.  Arachidonic acid is the precursor for many pro-
inflammatory prostaglandins and leukotrienes (39). If ARA is not used for the formation of 
pro-inflammatory molecules it undergoes further enzymatic reactions modulated by 
elongase and ∆ 6-desaturase and then β-oxidation (40).The end product of this series of 
reactions is n-6 DPA.  
Alpha-linolenic acid, an n-3 fatty acid, is the precursor to endogenously formed EPA.   
The formation of EPA from ALA is dependent on the same enzymes (∆ 6-desaturase, 
elongase, and ∆ 5-desaturase) used to convert LA to ARA. Eicosapentaenoic acid is a 
precursor for many anti-inflammatory prostaglandins, leukotrienes, and resolvins (41); it is 
also the metabolic intermediate preceding DHA during n-3 fatty acid metabolism.  Elongase 
adds a two carbon unit to EPA to form n-3 DPA.  Similar to ARA conversion to n-6 DPA, n-3 
DPA undergoes a series of reactions catalyzed by elongase and ∆ 6-desaturase and finally 
β-oxidation to form DHA (Figure 4).  
The conversion of ALA to EPA, DPA, and DHA primarily occurs in the endoplasmic 
reticulum of the liver (39).  According to a review of literature conducted by Child et al. (42) 
in 2008, the conversion efficiency of ALA to EPA, DPA and DHA has been shown to be 
greater in women than men (43-44).  The estimated conversion of ALA to EPA, DPA, and 
DHA in women of reproductive age was 21%, 6% and 9%, respectively (44).   However, it is 
worth noting the dietary factors influencing the rate of conversion during gestation are not 
yet fully understood.  Two major hypotheses exist about the conversion of ALA to EPA, DPA 
and DHA.  The first hypothesis states the conversion of ALA to long chain polyunsaturated 
fatty acids (LCPUFAs) is dependent on n6:n3 ratio in the diet (45).  For example, diets rich 
in LA and lacking in ALA result in greater ∆6 desaturase activity in the n-6 pathway (greater 
12 
 
conversion of LA to ARA). Similarly, diets low in LA and high in ALA would favor the 
metabolic pathway that produces EPA and possibly DHA (Figure 4).  The second hypothesis 
states the conversion of ALA to LCPUFAs is influenced by the absolute amounts of ALA and 
LA in the diet.  A tracer study conducted by Goyens et al. (46) indicated an increase in 
dietary ALA results in an increase of DHA synthesis and a decrease in dietary LA intake 
results in an increase in EPA synthesis.  However, placental transfer of EPA, n-3 DPA, and 
DHA endogenously formed from ALA is limited during pregnancy (47).  In conclusion, the 
consumption of preformed EPA, DPA, and DHA are preferred over endogenous formation to 
meet metabolic demands (48).  
18:2n-6 Linoleic Acid (LA)
18:3n-6 Gamma-linolenic Acid
20:3n6 Eicosatrienoic Acid
20:4n-6 Arachidonic Acid (ARA)
18:3n-3 Alpha-linolenic Acid (ALA)
18:4n-3 Stearidonic Acid
20:4n-3 Eicosatetraenoic Acid
20:5n-3 Eicosapentaenoic Acid (EPA)
22:5n-3 Docosapentanoic Acid (DPA)
22:6n-3 Docosahexaenioc Acid (DHA) 
Elongase
Delta 5 desaturase
Delta 6 desaturase
Elongase
 
 Figure 4:  Long Chain PUFA Biosynthesis Pathways.  Adapted from Gurr et al. (36).   
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d. Dietary recommendations and sources of LA, ALA, EPA, n-3 DPA and DHA  
According to Institute of Medicine (IOM) of the National Academies the Adequate 
Intake (AI) for LA of 12 g/d for non-pregnant women and 13 g/d for pregnant women are 
routinely met in the United States (10). The average US population intake of ALA reported 
by the NHANES III database is 1.33 g/d (49).  Additionally, women tend to consume more 
ALA then men (48). Sources of LA include nuts (e.g. almonds, Brazil nuts, and peanuts), 
terrestrial animal products (e.g. ham and chicken egg), and vegetable oils such (e.g. 
soybean, safflower, and corn) (11).  The AI for ALA for non-pregnant women is 1.1 g/day 
and 1.4 g/d for pregnant women; both AIs are routinely met in the American diet (10). The 
major sources of ALA include soybean, canola oil, and flaxseed oil (11).   
The NHANES III database reports only 25% of the population reported an intake of 
EPA and DHA; the average US population intake of EPA and DHA is 0.04 g/d (0.02 
%kcal/d), and of DHA is 0.07 g/d (0.03 %kcal/d) (49). No value was reported for DPA intake.  
There is no AI for EPA, n-3 DPA, or DHA.  However, the International Society for the Study 
of Fatty Acids and Lipids recommends at least 200 mg DHA per day throughout gestation 
(10).  Additionally, the American College of Obstetricians and Gynecologists and the United 
States Department of Agriculture Dietary (USDA) Guidelines Committee currently 
recommend 1-2 servings (20-50 g) of fish per week during pregnancy (5-510).   Main dietary 
sources of EPA, n-3 DPA, and DHA are fatty fish, seafood, fish oil supplements, algae 
supplements, and fortified foods (11) (e.g. Silk soy milk and Smart Balance Omega Plus 
Buttery Spread) (Table 1).  Meat and eggs also contain EPA, n-3 DPA, and DHA (12). 
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Table 1.  Food and supplement sources of ALA, EPA, n-3 DPA and DHA.  Adapted and 
modified from Nutritionist Nutritionist Pro Version 4.2.2 (2009) dietary intake analysis 
software (Axxya Systems; Stafford, TX) and the USDA Nutrient Database for Standard 
Reference.     
 
 e. Omega 3 fatty acids during pregnancy 
i) Maternal Health 
It is hypothesized that women who consume n-3 fatty acid during pregnancy may 
prevent preeclampsia and postpartum depression.  It is important to note the results 
highlighted in the following text are still controversial and further investigations are 
underway. 
Preeclampsia affects at least 5-8% of all pregnancies in the United States (US) (52).  
The symptoms of preeclampsia (edema, hypertension, and proteinuria) are associated with 
increased cardiovascular risk later in life for the mother (2).  The essential n-3 fatty acid ALA 
and the n-3 fatty acids EPA, DPA, and DHA prevent preeclampsia (1-2).  It was previously 
acknowledged in this review of literature that n-3 fatty acids are metabolic precursors of 
eicosanoids.  The eicosaniods thromboxane B3 and prostacyclin I3 have been hypothesized 
to prevent pre-eclampsia via vasoconstriction and platelet aggregation, respectively (53).   
Secher, Sereger, and Olsen conducted a series of studies (54-57) that used various levels 
of n-3 fatty acid supplementation and placebo oils during pregnancy to detect any change in 
Food  Serving  ALA (g) EPA (g) n-3 DPA (g) DHA (g) 
Salmon, Atlantic Farmed 3 oz  0.189 0.977 0.393 1.252  
Tuna, light canned in water 3 oz 0.002 0.040 0.018 0.190 
Nordic Natural Omega 3 fish oil 
supplement 
1 g capsule 0.140 0.330 Not reported 0.220 
Chicken breast, meat only raw 4 oz 0.011 0.000 0.004 0.015 
Silk Soy milk 8 oz 0.184 Not reported Not reported 0.032  
Smart Balance Spread Omega 
Plus Buttery Spread 
1 T 0.320 0.016 Not reported 0.016 
Large  Egg 1 item 0.052 0.015 0.000 0.034 
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eicosanoid production and incidence of preeclampsia.   The results of these studies indicate 
that n-3 fatty acid supplementation was more effective at preventing preeclampsia than 
placebo supplementation.   For example in one of the studies by this research group (57) 
2.7 g of fish oil, a source of n-3 fatty acids or a control regimen of olive oil or no supplement 
was given to each participant (n=47) between 30-37 week of gestation.  At week 37, a 
significantly greater increase in the eicosanoids thromboxane B3 and prostacyclin I3 was 
observed in the experimental group.  This increase in eicosaniods is believed to prevent 
hypertension during pregnancy via vasoconstriction (57-59).    
Postpartum depression occurs in roughly 13% of U.S. women after they have given birth 
(60). Symptoms include sadness, fatigue, insomnia, appetite changes, reduced libido, crying 
episodes, anxiety, and irritability (60). Postpartum depression has been linked to DHA 
depletion during gestation (4).  Recently, it has been hypothesized the increased risk of 
DHA depletion during the third trimester may trigger depression before delivery and/or set 
the stage for postpartum depression (4-5).  The relationship between maternal status of 
DHA and the onset of depression before delivery was shown by the Rees et al. (4).  During 
the third trimester of pregnancy women with no know prior diagnosis of depression 
underwent psychological evaluation.  Each woman was tested for current depression using 
the Edinburgh Depression Scale.  The psychological evaluation indicated 16 of the 22 
women enrolled in the study were depressed.  Analysis of plasma phospholipids indicated 
significantly lower levels of DHA and total n-3 fatty acids in the depressed women.  
Additionally, higher levels of DHA and total n-3 fatty acid measured in the non depressed 
women were associated with significantly lower odds of depression.  The association of 
depleted n-3 fatty acid levels with postpartum depression was examined by De Vriese et al. 
(5).  Significant depressed levels plasma PL and RBC PE fatty acid composition were 
observed in women who developed a postpartum depression as compared to the control 
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mothers.  They were unable to calculate the correlation between depression diagnosis and 
fatty acid compositions because onset of depression between women varied. 
ii) Fetal Health 
DHA is a major component of brain grey matter and retinal phospholipids (6).  
Clinical research shows n-3 fatty acids, specifically DHA, intake during pregnancy supports 
positive fetal neurodevelopment, motor skills and visual acquity (6-9).  Hibbeln et al. (61) 
measured the impact of maternal n-3 fatty acid consumption from fish during gestation on 
infant and adolescent neurodevelopment and motor skills development during the Avon 
Longitudinal Study of Parents and Children.  Infant/child cognition and motor skills were 
examined at several time points after birth.  Greater maternal intake of n-3 fatty acids during 
gestation was associated with significantly lower risk of suboptimum verbal IQ in the 
offspring at 8 year old (1-340 g fish/wk vs >340 g fish/wk: OR=1.43 and no fish intake vs 
>340 g fish/wk: OR=2.16, P<0.0001). Additionally, greater maternal intake of n-3 fatty acids 
was associated  with lower suboptimal risk for poorly developed motor skills in the infant at 
42 months of age (no fish intake vs >340 g fish/wk: OR=1.68, P<0.0001).  These results 
along with two well conducted longitudinal studies (62-64) indicate that consumption of 
foods containing DHA during pregnancy may prevent suboptimal neurodevelopment and 
poor motor skill development in offspring. 
  The retina has also been shown to contain high amounts of DHA at birth (63).  
Malcolm et al. (65) examined the role of maternal supplementation of DHA on infant 
development by measuring visual evoked potential maturation (VEP) and infant cord RBC 
DHA compositions.  A significant correlation was observed between VEP peak latencies and 
decreased levels of DHA composition in infant cord RBCs (β=0.38, P<0.001).  These findings 
are similar to results provided by other well respected labs (66-67) and indicate that 
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maternal DHA intake during pregnancy does support healthy retina development in 
neonates. 
In conclusion, n-3 fatty acids support a healthy pregnancy.  Women consuming n-3 
fatty acid during pregnancy may prevent preeclampsia and postpartum depression.  
Furthermore, those neonates born to mothers with poor n-3 fatty acid status can be born 
with a dysfunctional CNS, poor cognitive function, impaired vision, growth retardation, and 
reproductive failure, fatty liver and dry skin (68).     
     II.    Dietary intake assessment tools 
Accurate assessment of n-3 fatty acid intake during pregnancy may be useful in 
clinical settings and during nutrition related research.  Possible dietary assessment tools 
include the FFQ, weighed diet record, and 24-hour recall.   
a.   The food frequency questionnaire 
The FFQ is a dietary assessment tool commonly used because it is non-invasive and 
easy to analyze for a variety of population types and sizes over various lengths of time (one 
month to five years) (29-30).  The primary objective of the FFQ in clinical research is to 
discriminate between high and low consumption of episodically or non typically consumed 
foods and/or nutrients like n-3 fatty acids (29).  The FFQ can be designed to quantify 
episodic intake over time by assessing portion size and frequency.  It can be administered 
through an interview or by one’s self.  The FFQ has been used to estimate n-3 fatty acid 
intake in non-pregnant individuals (26-27).  No known studies exist that have the primary 
objective of determining the association of the FFQ with some other dietary assessment tool 
when intake of ALA, EPA, DPA, and DHA is measured in healthy pregnant women.  
However, the semi-quantitative FFQ may be the most suitable dietary assessment tool for 
measuring episodically consumed nutrients like dietary n-3 fatty acid intake in pregnant 
women. The validity of the FFQ is determined by exploring the association between the 
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FFQ and other intake and status reference methods (i.e. other dietary assessment tools 
and biomarkers, respectively) (29).     
b.   Dietary reference tools for the validation of the FFQ  
Choosing a reference method depends on funding availability and study design.  The 
weighed diet record and 24-hour recall have been used as a reference method when 
developing an FFQ to assess fatty acid intake in non-pregnant individuals (23-28).   
       i)   The weighed diet record 
The weighed diet record does not rely on memory and it can assess mean usual 
intake (i.e. intake of nutrients consumed nearly every day) for a group (29).  However, 
unless it is administered in multiple instances, it cannot always quantify episodic intake (22).  
The measurements obtained from the weighed diet record have shown to be superior to 
memory recall of portion sizes used during the FFQ and 24 hr recall (28-29).  A known pitfall 
of weighed records is possible decreased compliance over time when an individual is aware 
of the weighed amount of food he/she is consuming and the cumbersome act of weighing 
each individual food consumed (29-30).  The FFQ has demonstrated agreement with the 
weighed diet record for assessing dietary intake of multiple nutrients, including DHA (23).   
Sullivan et al. (26) determined the association between a semi-quantitative FFQ and 
a weighed diet record when LCPUFA intake was estimated in healthy male and female 
participants (n=53).  Repeatability of the FFQ was also tested 4 to 6 weeks later by re-
administration of the same FFQ.    The 28-item self administered semi-quantitative FFQ was 
designed to assess LCPUFA intake from the previous three months.  Frequency was 
assessed using ten options ranging from never to intake per day, week, and month.  Open 
ended questions allowed the subject to clarify fortification, brands, and types of meat.   
Serving size was established by comparing estimated portion sizes to a regular size dinner 
plate. The weighed food record was completed over two week days and one weekend day 
19 
 
by recording weight and food description.  Forty-five subjects completed the FFQ and 
weighed diet record.  Thirty-three subjects participated in the reproducibility of the FFQ.  The 
mean intakes of total LCPUFA, EPA, DPA, and DHA from the two FFQs did not differ 
significantly.  Spearman’s correlation coefficients between FFQ1 and FFQ2 were also 
significant for total LCPUFA (rho=0.88), EPA (rho=0.88), DPA (rho=0.90), and DHA 
(rho=0.87) (P<0.05). Spearman’s correlation coefficients between the FFQ and weighed diet 
record for total LCPUFA, EPA, DPA, an n-3, and DHA intake were rho= 0.75, rho=0.64, 
rho=0.62, and rho=0.72, respectively.  Bland-Altman plots also showed that no systematic 
variation existed between the two methods for assessing total LCPUFA, EPA and DHA.  
The Bland-Altman plots showed no systemic bias existed between the two dietary 
assessment methods when PUFA, EPA, and DHA were measured.  More specifically the 
Bland-Altman plots showed homoscedasticity or constant scatter of differences across the 
range of means (68).  Finally, data were classified into quintiles based on intake estimated 
by the FFQ and diet record; 49% of subjects were classified into the same quartile when 
intakes of n-3 LCPUFAs were estimated.  These results indicate an FFQ designed to assess 
specific nutrient intake, the measurements of intake can be characterized as valid, 
repeatable and shows agreement with the weighed diet record.  Furthermore, the unbias 
distribution of the Bland-Altman plots indicates the days in which the weighed diet record 
was collected episodically consumed nutrients were captured.    
Similarly, Broadfield et al. (27) customized a previously validated semi-quantitative 
FFQ to assess dietary fatty acids in healthy adults (n=31, demographics unspecified) using 
a weighed diet record as the reference method. The FFQ was adapted to collect greater 
detail about food items that contain fatty acids (e.g. dairy products and fats and oils used for 
spreading and cooking) consumed over the previous month.  The adapted FFQ assessed 
129 items by assigning commonly used portion sizes (e.g. slice of bread or teaspoon of 
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sugar) and verifying frequency of consumption as follows:  seven times per week, 2-3 times 
per week, or rarely-never.  The weighed diet record was collected over seven consecutive 
days and subjects were instructed to include names of all food and beverages consumed.  
Pearson and Spearman correlation coefficients were used to assess agreement between 
the two dietary assessment methods.  The mean intake of individual fatty acids assessed by 
the 7dDR was typically greater than the mean intake of individual fatty acids assessed by 
the FFQ apart from oleic acid, LA, and total n-6 fatty acid.  Pearson correlation coefficients 
were calculated to determine the relationship between the FFQ and weighed diet record for 
the  parametric data and were as follows for the energy adjusted data:  total fat (r=0.40), 
total SFA (r=0.80), palmitic acid (r=0.77), stearic acid (r=0.70), total MUFA (r=0.21), oleic 
acid (r=0.20), total PUFA (r=0.20), total n-6 (r=0.26), LA (r=0.24), DGLA  (r=0.62), and total 
n-3 (r=0.26).  Spearman correlation coefficient were calculated to determine the relationship 
between the FFQ and weighed diet record for ARA (rho=0.70), EPA (rho=0.50), and DHA 
(rho=0.37) because these were the only data to exhibit non normal distribution after being 
adjusted for energy.  These results indicated that an FFQ and weighed diet records show 
agreement when assessing dietary fatty acid intake.  However, the wide range of reported 
correlations may indicate that further refining of this particular FFQ may be needed.  
ii)  The 24-hour recall 
The primary objective of the 24-hour recall in the clinical setting is to measure mean 
usual intake or nutrients consumed nearly every day by a group (28).  The 24-hour typically 
recall collects intake from the preceding day, in a short amount of time (15-20 minutes) 
without altering normal intake (29-30).  The 24-hour recall relies on client memory.  It is 
usable in diverse populations and has a relatively less burdensome on the client than the 
diet record (29).  Randomly administered 24 hour dietary recalls reduce the possibility of 
influencing habitual eating patterns because they can be administered without anticipation 
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(28).  Like the weighed diet record, when used in multiple instances, the 24-hour recall has 
an increased chance of measuring episodically consumed nutrients such as n-3 fatty acids 
(68).  Disadvantages of the 24-hour recall may include difficulty estimating portion size 
without food models and variance between day to day intakes (19). The 24-hour recall has 
been less commonly used as a reference method than the weighed diet record to assess 
dietary fatty acid intake in non-pregnant individuals. 
In 2007, Segovia-Siapco (25) validated the use of a 171-item semi-quantitative FFQ 
against six randomly assigned 24 hour dietary recalls to assess nutrient intake in two 
experimental groups:  walnut supplemented diet and a control diet (n=87).  The FFQ was 
administered in person and the 24-hour dietary recalls were administered over the 
telephone.  The FFQ assessed the previous six months intake by documenting the following 
consumption frequencies:  1-3 times per month, 1 time per week, 2-4 times per week, 5-6 
times per week, 1 time per day, 2-3 times per day and so on.  Mean nutrient intake reported 
by the FFQ was higher than mean nutrient intake reported by the 24-hour recalls for all 
nutrients except protein, ALA, cholesterol, and alcohol.  As a result of attenuation the 
following equation was used to determine the relationship between the tools: 
r  r  1   s
 /sn  
Where r = corrected/de-attenuated correlation coefficient;  r = uncorrected/de-attenuated 
correlation coefficient between the FFQ and multiple 24-hour recalls; s
 = within-person 
variance of the multiple 24-hour recalls; s= between-person estimate of variance in the 
reference method (24-hour recalls); n= number of repeated measures of the dietary recalls.  
Statistically significant de attenuated correlation coefficients were found between the FFQ 
and 24-hour diet recall for adjusted total energy (r= 0.39), total carbohydrate (r=0.42), 
vegetable protein (r=0.43), total fat (r=0.51), polyunsaturated fat (r=0.77), LA (r=0.78), ALA 
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(r=0.79), and total fiber (r=0.60) (P<0.001).  Bland-Altman plots showed good agreement 
between the two tools when assessing ALA.  As a result of the variation between person 
ARA, EPA, and DHA could not be corrected for measurement error; these nutrients also 
exhibited some of the lowest correlations between the FFQ and 24-hour recalls:   ARA 
(r=0.14), EPA (r=0.20), and DHA (r=0.15).   These lower correlations may have resulted 
from administration of the 24-hour recall on a day(s) episodically consumed nutrients were 
not eaten.  This study suggests that a FFQ and 24-hour dietary recall show agreement for 
mean usual intake but not episodic intake of nutrients for the group.  This is a common 
limitation when assessing dietary intake. 
 III. aaaaBiological Measurements 
Dietary assessment tools have also shown agreement with biological measurements 
(33- 36). Biological measurements (i.e. isotopes and biomarkers) provide a relatively 
accurate assessment of fatty acid status because they are objective and do not rely on 
memory or compliance of the participant (33).  A disadvantage of biological measurements 
is that they do not reflect true absolute intake. This disadvantage is a result of the affects of 
digestion, absorption, uptake, utilization, metabolism, excretion, homeostatic mechanisms, 
and error associated by the biochemical measures themselves (33).  
a.   Isotopes 
Isotopes have recently become a means of assessing DHA status (32).  Isotopes are 
less expensive to analyze than blood biomarker, highly accurate, and do not require the 
same special handling as other biological samples (27).  The physiological influences of 
isotopes are not fully understood in humans, let alone pregnancy.  Therefore, the use of 
isotopes as a reference method to determine the best dietary tool to assess DHA status in 
pregnant women is inappropriate at this time. 
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b. Biomarkers 
Biomarkers used to assess n-3 fatty acid status are adipose tissue and blood (45).  
When determining the association of a biomarker to dietary intake, the data must be 
collected in a timeframe that is relative to the biomarker half life (t1/2).  For example, a FFQ 
designed to assess dietary intake over a year should be validated using adipose tissue 
because the estimated t1/2 of adipose tissue TAG is between 1 and 2 years (28).   Pregnancy 
occurs over a time frame of ten months that does not correspond with the half life of TAG 
found in adipose tissue.  Additionally collecting adipose biopsies may be perceived as too 
invasive and diminish participation levels.  Therefore, adipose is not a favorable biological 
reference method for the determining the association of dietary n-3 fatty acid intake and 
status in pregnant women.    
An FFQ designed to measure the previous month’s intake of fatty acids has been 
associated with RBC and plasma (t1/2 =50 days and t1/2=10 days, respectively) fatty acid 
status (33). The blood sample needed to assess RBC and plasma fatty status is collected 
via venipuncture.  Compared to an adipose biopsy this procedure is less invasive.  Both 
RBC and plasma fatty acid fractions have repeatedly shown positive correlations with n-3 
fatty acid intake measured by an FFQ in non-pregnant individuals (26-27).   
i) Blood Biomarkers 
Several studies have shown that n-3 intake measured by an FFQ correlates with 
plasma or RBC fatty acid status.  Intake is defined as dietary consumption of a specific 
nutrient; status is defined as the biological level of a specific nutrient as a result of intake.  
The use of plasma (PLs) and RBC (PE and CE) fatty acid biomarkers to assess status has 
become increasingly important because of the association of n-3 fatty acid, specifically DHA, 
with health.   
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 FFQ and blood biomarker associations in non-pregnant individuals 
      McNaughton et al. (69) determined the association between intake and status when 
PUFAs were measured in a subset of randomly selected adult participants (n=43; 18 males 
and 25 non-pregnant females) from an ongoing randomized controlled trial.  Dietary intake 
was measured by a self-administered FFQ (assessed food intake over the past 6 months) 
and weighed diet record (two non-consecutive days) collected every 2 months for 12 
months.  The FFQ consisted of 129 specific foods with nine frequency options ranging from 
‘never’ to ‘4+ times per day’.  Serving size was specified using household measurements 
(cups or spoons) and common sizes or portions of food items (1 slice of bread).  Cooking 
methods, take-out meals, added types of fats and oils used for cooking and added to foods, 
and nutritional supplements were assessed.  Non-fasting venous blood samples were 
collected and immediately processed.  Plasma PLs were separated and quantified using 
gas-liquid chromatography.  Mean intakes reported by the FFQ were not significantly 
different from mean intakes reported by the weighed diet record. Spearman’s correlation 
coefficients for the weighed diet record vs plasma FA were significant:  total n-3 (rho=0.33), 
total LCPUFA (rho=0.44), ARA (rho=0.35), and DHA (rho=0.43) (P<0.05).  Similarly, the 
FFQ vs plasma PLs correlation coefficients for total LCPUFA (rho=0.38), LA (rho=0.34), and 
DHA (rho=0.32) were significant (P<0.05). The triad method was used to estimate how well 
each correlation was related to true, but unknown intake. This measurement was termed 
validity coefficient (VC) and measured using the following equations: 
VCQT =   ; VCRT =   ; VCMT =     
Where rQR = correlation coefficient between the FFQ and weighed diet record; rQB = 
correlation coefficient between the FFQ and blood biomarker; rRB = correlation coefficient 
between the weighed diet and the blood biomarker. VCQT = validity coefficient between FFQ 
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and true intake; VCRT = validity coefficient between weighed diet record and true intake; 
VCBT =validity coefficient between blood biomarker and true intake.  The triad method 
indicated the validity of the FFQ was highest for total LCPUFA, EPA, and DHA (respectively 
r=0.63, r=0.62, r=0.62); the validity of the plasma fatty acid was highest for ARA, DHA, and 
total n-3 FA (r=1.0, r=0.83, r=0.78, respectively). The triad method found validity of the 
weighed diet record was highest for total n-3 FA, LCPUFA, and DHA (r=0.43, r=0.60, r=0.52, 
respectively).  Additionally, 42% of individuals were classified in the same quintiles when 
intakes of n-3 LCPUFAs were estimated using the FFQ and weighed diet record.  The 
results of this study indicate a positive relationship between the FFQ, weighed diet record, 
and plasma fatty acid biomarkers.  The weighed diet record was associated with the blood 
biomarkers more often than the FFQ.  These results are expected because the weighed diet 
record reflects short term intake and plasma PL fatty acid compositions reflect status from 
days (40) or weeks to months (70). However, it may be more appropriate to use the FFQ 
and RBC fatty acid compositions to understand the association between long term intake and 
status because there is a wide variation in plasma PLs over time (74).    
Sun et al. (71) examined the relationship between fatty acid intake collected via the 
semi-quantitative FFQ  with plasma and RBC fatty acid biomarkers and in women (n=306), 
ages 43-69 years during the Nurse’s Health Study.  Fatty acid intake from the previous year 
was assessed using a semi-quantitative FFQ (130+ food items) in 1984, 1986, and 1990 to 
determine mean usual intake for a group.  Cooking oil, fat for frying and baking, and the 
addition of butter or margarine to food were assessed by specifying portion size and the 
frequency of consumption.  Frequency was assessed as follows: never, less than a one per 
month, and 6 or more times per day.  Three FFQ questions targeted nonspecific intake of 
canned tuna and nonspecific intake of fish (i.e. dark meat fish and other fish).  Blood 
samples were collected via venipuncture, processed and analyzed by gas-liquid 
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chromatography for plasma and RBC lipid FA content.  Fat intake was reported as a percent 
of total fat consumed.  Fatty acid composition of the plasma and RBCs were reported as a 
percent of total fatty acids.  The fractions of plasma and RBCs measured (i.e. PLs, PE, and 
PC) were not specified.  Dietary DHA intake showed the strongest Spearman’s correlation 
with RBC (rho=0.56) and plasma (rho=0.48) fatty acid levels; EPA was correlated more with 
RBC fatty acids (rho=0.38) than EPA plasma fatty acids (rho=0.21).  Linoleic acid exhibited 
the third strongest correlation between intake and RBC and plasma fatty acids status 
(rho=0.25 and rho=0.24, respectively).  The correlation coefficients for ARA and DPA were 
near zero.  The correlation coefficient between intake and DHA RBC content in 1984, 1986, 
1990 was rho=0.41, rho=0.43, and rho=0.56, respectively. The correlation coefficient 
between intake and EPA RBC content in 1984, 1986, 1990 and cumulative time was 
respectively rho=0.30, rho=0.37, rho=0.38, and rho=0.41.  Similar correlation coefficients for 
DHA were found between plasma FAs and intake in 1984, 1986, 1990 and cumulative time 
(rho=0.33, rho=0.36, rho=0.48, and rho=0.44, respectively).  Average total plasma and RBC 
FA content were closely correlated (rho=0.72).  Overall, this study illustrates a correlation 
between dietary fatty acid intake and fatty acids composition in RBC and plasma; correlations 
were stronger for RBC fatty acids than for plasma acids.  These results suggests that RBC 
fatty acid analysis for n-3 content may be appropriate for long-term intake measurements 
collected via a FFQ (69).  Further investigation may warrant using different time variations 
(e.g. every 6 months vs. every 30 days) for assessing intake to determine if RBC fatty acid 
analysis is more appropriate to plasma fatty acid analysis when validating a FFQ because of 
the difference in each biomarker’s t1/2. 
Similarly, Sullivan et al. (22) validated the use of a semi-quantitative FFQ to assess 
LCPUFA intake against RBC and plasma fatty acid levels.  The FFQ was previously 
validated against a weighed diet record and tested for repeatability (21).   Fifty-three 
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subjects (20 males and 33 females) completed the FFQ.  Blood samples were collected via 
venipuncture, processed and analyzed for RBC and plasma fatty acid compositions (fractions 
not specified) using gas-liquid chromatography and the Folch method (73), respectively.  
Statistically significant Spearman’s correlation coefficients were reported between EPA and 
DHA intake and the RBC percent FA content (rho=0.40 and rho=0.39, respectively) 
(P<0.01).   Total LCPUFA intake also statistically correlated with the RBC total LCPUFA 
fatty acid composition content (rho=0.50, P<0.001).  Plasma fatty acid content was positively 
correlated with total dietary LCPUFA (rho=0.54), EPA (rho=0.54) and DHA (rho=0.48) 
(P<0.001).   These results suggest that RBC and plasma fatty acids are possible reference 
methods for validation of an FFQ for total and individual LCPUFA intake.  
FFQ and blood biomarker associations in pregnant individuals 
To date the number of FFQs validated to assess n-3 FAs against biomarkers in 
pregnant women is limited (16-20).  It is critical to document this population’s n-3 intake 
because of the role DHA plays during pregnancy (increased fetal/infant cognition and visual 
acuity) (6-9) and to clearly define DHA needs during pregnancy.  Otto et al. (16) assessed 
essential fatty acid (EFA) status (ALA and AA) using a FFQ in pregnant women (n=24) to 
investigate the influence of EFA intake prior to pregnancy and at week 10 of gestation.  
Plasma and RBC phospholipid fatty acid composition was determined prior to conception 
and at 6, 8, and 10 weeks of gestation using gas chromotography; EFA intake was 
assessed prior to conception and at 10 weeks gestation using a FFQ previously validated in 
pregnant women.  A significant increase in plasma phospholipids (palmitic acid, ARA, DHA, 
n-6, and n-3) from pre-pregnancy to week 10 of pregnancy was observed (P<0.0001).  Red 
blood cell phospholipids stearic and LA significantly declined during this time frame 
(P<0.0001).   No significant differences in dietary fatty acid intake were reported by the FFQ 
between preconception and week 10 of gestation.  Significant Spearman’s correlation 
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coefficients were found between pre-pregnancy dietary DHA intake and DHA plasma 
phospholipids (rho=0.64, P=0.009) and DHA RBC phospholipids (rho=0.65, P=0.007).  At 
wk 10 of gestation, only dietary LA intake was significantly correlated with LA plasma 
phospholipids (rho=0.67, P=0.004) (9).  The lack of significant correlations between dietary 
fatty acid intake and biomarker levels during pregnancy may be a result of the repartitioning 
of fatty acids to the fetus for development.  The physiological changes during pregnancy are 
complex and necessary to fulfill the needs of the growing fetus.  The results of this study 
indicate some ability to detect fatty acid status in early pregnancy when using a FFQ.  
However, because of the changes in metabolism throughout pregnancy it is desirable to 
look at the association between intake and status at different points of gestation through a 
single study or through multiple studies to fully fatty acid needs in pregnant women.   
De Vriese et al. (74) aimed to describe the relationship between dietary intake of 
LCPUFA and LCPUFA compositions in maternal and umbilical plasma PLs and CEs at 
delivery.  Thirty pregnant women completed the same FFQ (previously validated in pregnant 
women (16)) between 6-22 wks gestation and between 32-40 wks gestation to assess fat 
intake from the previous month. There was no significant difference in dietary intake of fatty 
acids between the FFQs; the FFQ measurements were averaged for comparison against the 
biomarkers.  At birth maternal and umbilical venous blood samples were collected and 
analyzed for fatty acid compositions using the Folch method (71).  Pearson’s correlation 
coefficients were measured.  Significant correlations were found between maternal dietary 
fatty acid intake and maternal plasma PLs for LA PL (r=0.53), ALA CE (r=0.53), EPA PL 
(r=0.48), DHA PL (r=0.52), EPA + DHA PL (r=0.53) and total n-6 PL (r=0.51) and DHA CE 
(r=0.39), EPA + DHA CE (r=0.44) (P<0.05).  Significant correlations between average 
maternal fatty acid intake and umbilical plasma PL fatty acids were only found in EPA  PL 
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(r=0.59, P<0.01) and total n-6 PL (r=0.38, P<0.05).  Regardless of the fact that maternal 
blood samples were not collected at the time the FFQs were administered the findings of 
this study suggest an FFQ designed for a specific target population to assess dietary intake 
of LCPUFAs correlates with plasma fatty acids in the mother and infant at birth.   
Parra et al. (15) compared PUFA dietary intake and RBC status in pregnant women 
during the third trimester of pregnancy.  Dietary intake and RBC fatty acid compositions were 
analyzed from a subset of an ongoing study (n=35).  A semi-quantitative FFQ including 104 
items was used to collect dietary intake of n-3 PUFAs over the previous year.  Specific food 
groups were targeted because of the known fat composition of these foods (eggs, fish, oils, 
milk, and terrestrial meat).  Intake was assessed over the past year; frequency ranged from 
never up to 6 times per day.  Red blood cells were analyzed using liquid gas 
chromatography (analyzed fraction of RBCs not defined).  Pearson correlation coefficients 
between dietary intake and RBC were significantly associated when ALA (r=0.32), 
EPA(r=0.36), and DHA (r=0.35) were measured (P≤0.05). A linear regression model 
demonstrated that RBC PUFA analysis was predicted by dietary intake of ALA (β=0.52), 
DHA (β=0.30), and AA (β=0.49).  This study suggests that a FFQ may be a reliable method 
of documenting PUFA intake in pregnant women in comparison to RBC fatty acid levels.  
However, further research is needed to document specific PUFA intake (e.g. DHA and EPA) 
and to assess agreement between plasma and RBC fatty acid status. 
In conclusion, fatty acid compositions of RBC and plasma fractions may be useful 
biological measurements to determine the association between maternal fatty acid status 
and dietary intake of fatty acids during pregnancy. The rapidly increasing body of research 
centered on DHA intake during pregnancy necessitates a validated assessment tool to 
ensure accurate reporting of DHA intake and status.  Literature suggests the FFQ might be 
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the most appropriate tool to assess long term DHA status in pregnant women.  The 
validation of the FFQ as a DHA assessment tool can be achieved by assessing its 
agreement between another dietary assessment tool (weighed diet record) and blood 
biomarkers (erythrocyte and plasma fatty acid compositions).  
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CHAPTER 3:  Methods 
A prospective observational study was conducted over two years in Bozeman, Montana 
and Ames, Iowa.  Participants were recruited via newspaper advertisements, flyers, word of 
mouth, physician’s offices, and Craig’s list postings. Inclusion criteria were between the ages of 
18-45 years, non-smoker, and singleton pregnancy.  Exclusion criteria were history of type 2 
diabetes, hypertension, heart disease, chronic renal disease, and not residing in surrounding 
the communities.  Eligible participants included in the convenience sample signed an informed 
consent form approved by the Montana State University (MSU) Institutional Review Board (IRB) 
or by the Iowa State University (ISU) IRB according to the location they participated in the study.  
Subjects were enrolled between weeks 15-35 of gestation.  All participants completed a 
demographic survey to collect age, annual income, highest grade of education completed, 
number of parities, pre-pregnancy weight, and marital status.  Self reported height was 
documented in feet and inches.  A portable Sunbeam analog scale (Boca Raton, FL) was used 
to record weight to the nearest tenth of a pound.   
To fulfill  the needs of Specific Aim #1 and 2, subjects were recruited and enrolled 
between weeks 15-35 of gestation (n=136).  A subset of these participants (n=63) was used to 
address Specific Aim #3.   
 
 
 
 
 
 
 
 
Figure 4.  Subject Population and Specific Aim Flow Chart. 
Specific Aim 1 & 2 
  MT subjects (n=65) 
+ 
IA subjects (n=71) 
Specific Aim 2 
Subset of MT subjects (n=30) 
+ 
Subset of IA subjects (n=33) 
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              I.  Assessment of dietary intake  
   Diet data were collected by trained interviewers using a semi-quantitative FFQ and 
weighed 3-day diet record (3dDR).  Subjects were randomly assigned to one of two orders to 
avoid bias in the data collection:  FFQ prior to weighed 3dDR or 3dDR prior to FFQ. 
a. Food frequency questionnaire 
  A semi-quantitative FFQ was developed by the principal investigator and several 
graduate research assistants.  The FFQ included 107-food items and estimated dietary intake of 
total n-3 fatty acids, ALA, EPA, n-3 DPA, and DHA from the previous 30 days.   The FFQ was 
administered through a face-to-face interview and took approximately 45 minutes to complete.  
All research staff members were trained how to administer the FFQ prior to collecting data 
through the following steps:  1) observed at least two FFQ interviews; 2) completed an FFQ 
interview as a mock research subject; 3) completed a FFQ interview as the interviewer with a 
mock research subject; and 4) completed their first two FFQ interviews with actual research 
subjects under supervision of a previously trained staff member. Frequency of food intake was 
assessed using the following ranges: 1-4 times per day, 1-7 times per week or 1-3 times per 
month.  Food models and measuring cups were used to estimate portion sizes.   Food 
categories on the FFQ included milk products, yogurt/ice cream, fats and oils, poultry/meat, fish, 
eggs, vegetables, fruits, snacks, grains, fast food, and supplements.  When assessing poultry, 
meat, and fish consumption the interviewer further inquired about specific meat cuts (e.g. 
skinless boneless chicken breast vs chicken thigh with skin) and types of fish (white tuna 
canned in water vs raw albacore tuna).  Duplicate assessment of cooking fats was avoided by 
documenting food items as raw or unprepared and by recording butter and margarine spread 
when used for cooking and spreading, but not for baked goods.  Researchers indirectly inquired 
about supplements and foods commonly fortified with ALA, EPA, and DHA to avoid influencing 
the subjects from seeking out and consuming n-3 fatty acid fortified foods and supplements.  If a 
33 
 
subject reported consuming a supplement on only one of the dietary assessment tools the 
interviewer confirmed its consumption or lack of consumption over the phone with the research 
subject.   
b. Weighed diet record 
  Participants received detailed instruction on how to complete a weighed 3dDR using a 
Cuisinart SA-110A scale (Cuisinart, East Windsor, NJ). Subjects were given seven days to 
record three days of diet records:  two week days and one weekend day diet.  These days were 
not required to be consecutive.  After data collection was complete, research staff reviewed the 
dietary log with the subject present to ensure complete record taking and to clarify any 
discrepancies that may exist on the record.   
            II. Diet analysis 
Diet data was analyzed using Nutritionist Pro Version 4.2.2 (2009) dietary intake analysis 
software (Axxya Systems; Stafford, TX) by trained research staff.   Before staff members were 
allowed to analyze dietary data they completed a standardized diet record developed by the 
principal investigator using Nutritionist Pro and were required to be within ± 2% of the average 
kilocalories, carbohydrate, fat, and protein content as determined by data outputs of previously 
trained staff.  The FFQ and 3dDR for each subject were entered into the nutrient database by 
the same research staff to ensure consistent food selections between records.  Whenever 
possible, food items selected during the analysis process were from the USDA Nutrient 
Database for Standard Reference because brand name foods within the nutrient database 
rarely contain complete dietary information for dietary fatty acids.  Fortified foods and 
supplements containing ALA, EPA, and DHA reported via the FFQ and 3dDR were manually 
added to the nutrient database.  Dietary information for fortified foods was determined via food 
labels, internet searches and through direct contact with the food manufacturer.   Dietary intake 
of DPA was analyzed using the USDA Nutrient Database for Standard Reference website (75) 
because Nutritionist Pro does not include DPA composition of food.  Dietary analysis output was 
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further reviewed by the first author to ensure the food with the most complete fat composition 
was selected and to ensure that the DHA and/or DHA + EPA supplements choices matched 
between the FFQ and weighed diet record.   
  III. Fatty acid blood biomarker measurements 
           a. Maternal blood sample collection 
A fasted (no food or calorie containing beverages for at least eight hours) maternal 
venous blood sample was collected in an EDTA vacutainer (Becton Dickenson, Franklin Lakes, 
NJ) to coincide with dietary data collection.  Vacutainers containing blood were placed on ice 
immediately after collection to maintain the integrity of the sample. Once the blood samples 
were returned to the MSU Nutrition Research Lab or the ISU campus they were centrifuged at 
2000 g for 10 minutes at 4 degrees C to separate the plasma from the RBC.   Plasma was 
stored at -80 degrees C.     The remaining RBCs were washed with saline/EDTA (9 g/Liter 
sodium chloride and 1.14 g/Liter sodium EDTA in deionized water) and centrifuged at 2000g for 
10 min at 4 degrees C.  The buffy layer was removed and the wash step was repeated one 
more time to ensure all plasma had been washed away from the RBC.  The RBCs were also 
stored at -80 degrees C.           
          b. Fatty acid analysis  
Frozen plasma and RBCs samples were shipped on dry ice to The University of British 
Columbia, Nutrition Research Lab for analysis in November 2008, March 2009, October 2009 
and January 2010.  This is a well established lab that has conducted fatty acid analysis for over 
25 years.   
Plasma lipids were extracted using a modified Folch (26) extraction procedure using 2 
parts sample in saline, 3 parts methanol and 6 parts chloroform.  After vortexing and 
centrifugation at 2500 g for 10 minutes, the lower organic phase was collected.  The aqueous 
phase was washed with additional chloroform and again the organic phase was collected, 
pooled with the first organic phase then dried under nitrogen to obtain a total lipid extract. 
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Red blood cell lipid classes were separated using TLC.  Lipid fractions were recovered 
and converted to their respective methyl esters by gas chromatography with flame ionization 
using an Agilent 6850 gas chromatogram (Agilent Technologies Inc., Santa Clara, CA) with an 
Agilent HP-88 capillary column (30 m x 0.35 mm internal diameter x 20-µ film thickness).  
Agilent Chemstation software (Agilent Technologies Inc., Santa Clara, CA) was used to quantify 
the fatty acid peaks as a percent weight (g/100 g fatty acid) of each fatty acid based on the area 
under the curve.   
     IV. Statistical analysis   
Specific Aim #1:  Descriptive statistics were calculated for the total n-3 fatty acid and 
individual fatty acid intake including ALA, EPA, and DHA.  These statistics included mean, 
median, mode, range, and standard deviation.  Additionally, a Kolmogorov–Smirnov (K-S) test 
was used to test for a normal distribution of n-3 fatty acids intakes collected via the FFQ and 
3dDR.     
Specific Aim #2:  Spearman’s Correlation coefficients determined the relationship 
between the daily intakes of total n-3 fatty acid and individual fatty acid estimated by the FFQ 
and the weighed 3dDR.   Data were classified into three groups based on DHA intake estimated 
by the 3dDR.  The lowest group, <70 mg DHA/day, was chosen as a reference to the fetal DHA 
needs of 67 mg DHA/day during the third trimester (7).  The highest group, ≥ 200 mg DHA/day 
was based on the daily recommendation for maternal intake of 200 mg DHA/day throughout 
gestation (11). 
Specific Aim #3:  Descriptive statistics were calculated for the total DHA content of the 
RBC and plasma.  A K-S test was performed to test for a normal distribution of n-3 fatty acids 
for blood biomarkers.  Spearman’s correlation coefficients determined the relationship between 
the daily intakes of total n-3 fatty acid and individual fatty acid estimated by the FFQ and 3dDR 
and the fatty acid blood biomarkers. 
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Data were analyzed using Predictive Analytical Software (PASW) 18.0.0 (SPSS Inc, 
Chicago, IL).  Statistical significance was set at P<0.05.     
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CHAPTER 4:  Dietary Intake of total and individual n-3 fatty acids by pregnant women:  
associations between the semi-quantitative food frequency questionnaire and weighed 
diet record 
A paper to be submitted to the Journal of the American Dietetic Association 
Rebecca Filipowicz, Christina G. Campbell, PhD, RD.  
Abstract 
Introduction 
Omega 3 (n-3) fatty acids are beneficial to maternal and fetal health.  No known studies 
have the primary objective of determining the association of the food frequency questionnaire 
(FFQ) with some other dietary assessment tool when total and individual n-3 fatty acids intakes 
are estimated in pregnant women from non-coastal communities.   
Objective   
To determine the ability of the semi-quantitative FFQ to estimate intake of total n-3, 
alpha-linolenic acid (ALA), eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA), and 
docosahexaenoic acid (DHA) in pregnant women from non-coastal communities. 
Methods 
Intake of total and individual n-3 fatty acids were estimated using the FFQ and weighed 
3dDR in 136 healthy, pregnant women between 15-34 weeks gestation during a prospective 
observational study. Estimated intakes of total n-3, ALA, EPA, DPA, and DHA collected by FFQ 
and 3dDR were analyzed using Nutritionist Pro (Axxya Systems 9.2.2).  Spearman’s Correlation 
coefficients were conducted to determine if the FFQ and 3dDR were associated.  Data were 
classified into three groups based on DHA intake estimated by the 3dDR to determine if the 
dietary assessment tools agreed when <70 mg DHA/day, 70-199 mg DHA/day, or ≥200 mg 
DHA/day was consumed.   
Results 
38 
 
Spearman’s correlations indicated a significant positive association between the FFQ 
and weighed 3dDR for intake of total n-3 (rho=0.98), ALA (rho=0.27), EPA (r=0.56) and DHA 
(r=0.66) (P<0.01).  Agreement between estimated intake of DHA between the FFQ and 3dDR 
was found to be 58% for all levels of intake.  The FFQ was better at determining episodic intake 
of DHA, 13 individuals reported consuming <70 mg DHA/day on the 3dDR and ≥200 mg 
DHA/day on the FFQ. 
Conclusion 
The semi-quantitative FFQ is an appropriate dietary assessment tool to estimate intake 
of total n-3, ALA, EPA and DHA and correlates well with the weighed 3dDR.      
Introduction      
Consumption of omega 3 (n-3) fatty acids during gestation has been shown to benefit 
mother and baby.  The essential n-3 fatty acid alpha-linolenic acid (ALA) and the n-3 fatty acids 
eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA), and docosahexaenoic acid (DHA) 
support maternal (1-5) and fetal health (6-9). DHA is a major component of brain grey matter 
and retinal phospholipids (6).  The Adequate Intake (AI) for ALA for pregnant women is 1.4 g/d 
and is routinely met in the American diet (10).  Clinical research shows DHA intake during 
pregnancy supports positive fetal visual acuity and motor skills development (6-9). Maternal 
intake of at least 200 mg DHA per day throughout gestation is recommended to support a 
healthy pregnancy, to prevent maternal depletion of DHA, and to meet the increased fetal 
demands of 67 mg DHA per day during the third trimester, a period of rapid fetal growth (11-13).  
At this time there are no dietary recommendations for EPA and DPA intake during pregnancy.  
Common sources of ALA include soybean, canola oil, and flaxseed oil (12).  Dietary sources of 
DHA are fatty fish, seafood, meat, and eggs (13); EPA and DPA are routinely found in the same 
dietary sources as DHA (14).  Fortified foods and supplements are also consumable sources of 
ALA, EPA and DHA.         
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Accurate estimation of n-3 fatty acid intake during pregnancy may be useful in clinical 
settings and during nutrition related research.  Possible dietary assessment tools include the 
weighed diet record, 24-hour recall, and the food frequency questionnaire (FFQ).  Dietary intake 
estimated by a weighed diet record does not rely on memory and is documented over several 
days.  A known limitation of the weighed record is possible decreased compliance over time 
when an individual is aware of the weighed amount of food he/she is consuming and the 
cumbersome act of weighing each individual food consumed (16).  The 24-hour recall estimates 
intake from the preceding day, in a short amount of time (15-20 minutes) without altering normal 
intake.  It is usable in diverse populations and has a relatively low burden on the client.  A 
possible limitation of the 24-hour recall is the reliance on memory to estimate intake.   The 
weighed diet record and 24-hour recall measure mean usual intake of food or nutrients 
consumed nearly every day by a group (16).  Unless the weighed diet record and 24-hour recall 
are administered in multiple instances, neither tool consistently measures episodic intake nor 
sporadically consumed nutrients, like n-3 fatty acids.  The weighed diet record has been more 
commonly used as a reference method than the 24 hour recall to assess dietary fatty acid intake 
in non-pregnant individuals (17-21).  The strengths and limitations of both tools have been 
discussed thoroughly elsewhere (22-24). 
The semi-quantitative FFQ is cost effective and has been used to measure episodic or 
sporadic intake from the previous 30 days to 5 years in a wide variety of populations (15-20).  
The FFQ has been used to estimate n-3 fatty acid intake in non-pregnant individuals (17-21).  
No known studies exist that have the primary objective of determining the association of the 
FFQ with some other dietary assessment tool for total and individual n-3 fatty acids in pregnant 
women from non-coastal communities.  However, the semi-quantitative FFQ may be a suitable 
dietary assessment tool to estimate episodically consumed nutrients such as dietary n-3 fatty 
acids over long periods of time.    
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When determining the association between dietary assessment tools measurement error 
and non-matching data is a limitation.   Sources of error may be caused by collecting data on 
non-consumption days, misreporting frequency of consumption or portion size, and poor food 
description (25).   Measurement error can lead to the over- or underestimation of intake in 
comparison to the other tool.  It is important to note there is no one perfect dietary assessment 
tool.  When validating a dietary assessment it is necessary to have a reference dietary 
assessment tool and to recognize the strengths and limitations of both tools.  
The purpose of the present study was to compare the estimated intakes of total and 
individual n-3(ALA, EPA, DPA, and DHA) collected by FFQ and weighed 3-day diet record 
(3dDR) in women 15-35 weeks pregnant living in a non-coastal community. It was hypothesized 
that a significant association between the FFQ and 3dDR for total and individual n-3 fatty acid 
estimated intakes would be found. 
Methods 
  A prospective observational study was conducted over two years in Bozeman, Montana 
and Ames, Iowa.  Participants were recruited via newspaper advertisements, flyers, word of 
mouth, physician’s offices, and Craig’s list postings. Inclusion criteria were between the ages of 
18-45 years, non-smoker, and singleton pregnancy.  Exclusion criteria were history of type 2 
diabetes, hypertension, heart disease, chronic renal disease, and not residing in surrounding 
the communities.  Eligible participants included in the convenience sample signed an informed 
consent form approved by the Montana State University (MSU) Institutional Review Board (IRB) 
or by the Iowa State University (ISU) IRB according to the location they participated in the study.  
Subjects were enrolled between weeks 15-35 of gestation.  All participants completed a 
demographic survey to collect age, annual income, highest grade of education completed, 
number of parities, pre-pregnancy weight, and marital status.  Self reported height was 
documented in feet and inches.  A portable Sunbeam analog scale (Boca Raton, FL) was used 
to record weight to the nearest tenth of a pound.   
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Assessment of Dietary Intake  
   Diet data were collected by trained interviewers using a semi-quantitative FFQ and 
3dDR.  Subjects were randomly assigned to one of two orders to avoid bias in the data 
collection:  FFQ prior to weighed 3dDR or 3dDR prior to FFQ.  
Food Frequency Questionnaire 
A semi-quantitative FFQ was developed by the principal investigator and several 
graduate research assistants.  The FFQ included 107-food items and estimated dietary intake of 
total n-3 fatty acids, ALA, EPA, n-3 DPA, and DHA from the previous 30 days.   The FFQ was 
administered through a face-to-face interview and took approximately 45 minutes to complete.  
All research staff members were trained how to administer the FFQ prior to collecting data 
through the following steps:  1) observed at least two FFQ interviews; 2) completed an FFQ 
interview as a mock research subject; 3) completed a FFQ interview as the interviewer with a 
mock research subject; and 4) completed their first two FFQ interviews with actual research 
subjects under supervision of a previously trained staff member. Frequency of food intake was 
assessed using the following ranges: 1-4 times per day, 1-7 times per week or 1-3 times per 
month.  Food models and measuring cups were used to estimate portion sizes.   Food 
categories on the FFQ included milk products, yogurt/ice cream, fats and oils, poultry/meat, fish, 
eggs, vegetables, fruits, snacks, grains, fast food, and supplements.  When assessing poultry, 
meat, and fish consumption the interviewer further inquired about specific meat cuts (e.g. 
skinless boneless chicken breast vs. chicken thigh with skin) and types of fish (white tuna 
canned in water vs. raw albacore tuna).  Duplicate assessment of cooking fats was avoided by 
documenting food items as raw or unprepared and by recording butter and margarine spread 
when used for cooking and spreading, but not for baked goods.  Researchers indirectly inquired 
about supplements and foods commonly fortified with ALA, EPA, and DHA to avoid influencing 
the subjects from seeking out and consuming n-3 fatty acid fortified foods and supplements.  If a 
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subject reported consuming a supplement on only one of the dietary assessment tools the 
interviewer confirmed its consumption or lack of consumption over the phone with the research 
subject.   
Weighed Diet Record 
Participants received detailed instruction on how to complete a weighed 3dDR using a 
Cuisinart SA-110A scale (Cuisinart, East Windsor, NJ). Subjects were given seven days to 
record three days of diet records:  two week days and one weekend day diet.  These days were 
not required to be consecutive.  After data collection was complete, research staff reviewed the 
dietary log with the subject present to ensure complete record taking and to clarify any 
discrepancies that may exist on the record.   
Diet Analysis 
Diet data was analyzed using Nutritionist Pro Version 4.2.2 (2009) dietary intake 
analysis software (Axxya Systems; Stafford, TX) by trained research staff.   Before staff 
members were allowed to analyze dietary data they completed a standardized diet record 
developed by the principal investigator using Nutritionist Pro and were required to be within ± 
2% of the average kilocalories, carbohydrate, fat, and protein content as determined by data 
outputs of previously trained staff.  The FFQ and 3dDR for each subject were entered into the 
nutrient database by the same research staff to ensure consistent food selections between 
records.  Whenever possible, food items selected during the analysis process were from the 
USDA Nutrient Database for Standard Reference because brand name foods within the nutrient 
database rarely contain complete dietary information for dietary fatty acids.  Fortified foods and 
supplements containing ALA, EPA, and DHA reported via the FFQ and 3dDR were manually 
added to the nutrient database.  Dietary information for fortified foods was determined via food 
labels, internet searches and through direct contact with the food manufacturer.   Dietary intake 
of DPA was analyzed using the USDA Nutrient Database for Standard Reference website (26) 
because Nutritionist Pro does not include DPA composition of food.  Dietary analysis output was 
43 
 
further reviewed by the first author to ensure the food with the most complete fat composition 
was selected and to ensure that the DHA and/or DHA + EPA supplements choices matched 
between the FFQ and weighed diet record.   
Statistical Analysis   
Mean and median values for daily total n-3 fatty acid and individual n-3 fatty acid intake 
were determined from the semi-quantitative FFQ and weighed 3dDR.  A Kolmogorov–Smirnov 
(K-S) test was used to test for a normal distribution of n-3 fatty acid intake data from the FFQ 
and 3dDR.  Spearman’s correlation coefficients were chosen because the data were non-linear 
and determined the rank relationship between estimated total n-3 and individual n-3 fatty acid 
intakes measured by the FFQ and weighed 3dDR.  Data were classified into three groups based 
on DHA intake estimated by the 3dDR.  The lowest group, <70 mg DHA/day, was chosen as a 
reference to the fetal DHA needs of 67 mg DHA/day during the third trimester (12).  The highest 
group, ≥ 200 mg DHA/day was based on the daily recommendation for maternal intake of 200 
mg DHA/day throughout gestation (11-13). Data were analyzed using Predictive Analytical 
Software (PASW) 18.0.0 (SPSS Inc, Chicago, IL).  Statistical significance was set at P<0.05.     
Results 
Subject Characteristics                                                                                                                                                     
 A total of 142 women (n=64 from MT and n=78 from IA) were recruited for participation.  
Mean (± standard deviation) age and pre-pregnancy body mass index (BMI) of participants were 
30 ± 4 years and 23.4 ± 4.5 kg/m2, respectively.  The mean week of gestation was 29 weeks 
and 1 day ± 3 weeks and 4 days.  Age, pre-pregnancy BMI, and week of gestation did not differ 
significantly between participants from MT and IA. Therefore, dietary data were analyzed as one 
group regardless of location.  The majority of participating women (92%) were Caucasian, while 
the remaining 8% of the study population was comprised of Native American (n=1), Asian (n=6), 
African American (n=2), or other (n=1).  Approximately 41% of women had completed some 
graduate/professional school, half had completed 1-4 y of college, and less than 10% had only 
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some degree of secondary education.  Slightly more than one-third of the participant’s annual 
income was greater than $75,000, 47% had an annual income which ranged between $20,001 
and $75,000, and approximately 20% identified as students had an annual income less than 
$20,000.  One hundred thirty-two women reported being married, twelve women were single 
and one woman was divorced.  Reported ethnicity, education level, annual income level, and 
marital status did not significantly differ between participants from either location. 
 After signing informed consent and reporting demographic data, six women withdrew 
from the study before collecting any dietary data.  Three participants did not complete a 
weighed 3dDR and were excluded from the statistical analysis.  The final data analysis included 
136 women.   
FFQ and weighed 3dDR analysis 
Statistical analysis was performed with (n=136) and without (n=109) EPA and DHA 
supplementation.  No significant differences were observed when supplements were included or 
excluded from statistical analysis of dietary intake data; therefore, dietary data with EPA and 
DHA supplementation was included in the final analysis.  Few individuals consumed fortified 
food and it was not a statistically significant source of EPA and DHA (data not shown).   
Total n-3 fatty acid intake represents the sum of all ALA, EPA, DHA, and DPA fatty acids 
reported by the dietary assessment tools.  A K-S tested indicated non-normal distributions for 
total n-3, ALA, EPA, DPA, and DHA on the FFQ and 3dDR (P<0.01). The FFQ estimated 
greater mean intakes than the weighed 3dDR for total n-3 fatty acid (2.414 ± 1.970 g/d vs. 2.486 
± 2.067 g/d, respectively), ALA (1.932 ± 1.772 g/d vs. 1.637 ± 0.986 g/d, respectively), EPA 
(0.050 ± 0.070 g/d vs. 0.047 ± 0.093 g/d, respectively), DPA (0.350 ± 0.616 g/d vs. 0.023 ± 
0.045 g/d, respectively), and DHA (0.095 ± 0.104 g/d vs. 0.081 ± 0.140 g/d, respectively). The 
median and 5-95th percentiles for all participants are shown in Table 1.   
The semi-quantitative FFQ and weighed 3dDR had positive associations for total n-3 
(rho=0.98), ALA (rho=0.28), EPA (rho=0.56), and DHA (rho=0.66) for all participants (n=136) 
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(P<0.01).  No significant association was found between estimates of n-3 DPA intakes from the 
FFQ and 3dDR (rho=0.08).  Outliers were identified as those individuals whose reported intake 
on the FFQ was greater than ± 2 standard deviations from the mean.  Significant associations 
were also found for n-3, ALA, EPA, and DHA when outliers were removed from the analysis 
(Figure 1).  Associations between estimated intakes collected via the FFQ and weighed 3dDR 
without outliers were maintained for total n-3 fatty acid and DHA, increased for ALA and EPA, 
and decreased for DPA.  
Dietary intake data for all subjects (n=136) was divided into groups using DHA intake 
estimated from the 3dDR. When <70 mg DHA/day was estimated via the weighed 3dDR, 46 
individuals reported consuming <70 mg DHA/day on the FFQ, 20 individuals reported 
consuming 70-199 mg DHA/day, and 12 individual reported consuming  ≥200 mg DHA on the 
FFQ.  Within the second group defined by DHA intake on the 3dDR, 70-199 mg DHA/day, 6 
individuals reported consuming <70 mg DHA/day via the FFQ, 6 individuals reported consuming 
70-199 mg DHA/day on both the FFQ and 3dDR, whereas 5 individuals reported consuming 
≥200 mg DHA/ day on the FFQ.  Finally, within the highest group (≥200 mg DHA/ day), 9 
individuals reported consuming <70 mg DHA/day via the FFQ, 5 individuals reported consuming 
70-199 mg DHA/day, and 27 individuals reported consuming ≥200 mg DHA/day.  In summary, 
58% agreement between the FFQ and the 3dDR was found whereas 42% disagreement was 
revealed.     
Discussion 
The results of this study demonstrate a good association between estimated intakes of 
n-3, ALA, EPA, and DHA from a semi-quantitative FFQ and a 3dDR in pregnant women living in 
non-coastal communities. The mean intake of n-3 fatty acids from the FFQ was higher than 
those from the 3dDR.  For example, during this study some subjects reported consuming foods 
containing EPA and DHA on the FFQ at least two times per week and when their 3dDR was 
46 
 
reviewed little to no foods containing EPA and DHA were documented.  This may be a result of 
overestimation of frequency and portion size by the FFQ and/or decreased compliance during 
the collection of the diet record (17, 31).  This observation may be magnified by the fact the 
weighed diet record may report 0 mg of intake for episodically consumed nutrients (e.g. EPA 
and DHA) (28-29).  
No known study conducted in pregnant women has focused on the association between 
dietary intake of n-3 fatty acids, specifically ALA, EPA, DPA and DHA, estimated by an FFQ 
with a dietary reference method such as the weighed 3dDR; therefore, it may be more 
appropriate to compare the findings of this study to those found in non-pregnant individuals 
assessing n-3 fatty acids. Our findings were significantly associated but to a less extent, 
specifically for n-3 DPA, than the results from a study conducted by Sullivan et al. (19).  A 28-
item self administered semi-quantitative FFQ, designed to measure intake from the previous 3 
months, and a weighed diet record were used estimate long chain polyunsaturated fatty acid 
(LCPUFA) intake in healthy male and female participants (n=53).  Spearman’s correlation 
coefficients between the FFQ and weighed diet record for total LCPUFA, EPA, n-3 DPA, an n-3, 
and DHA intake were rho= 0.75, rho=0.64, rho=0.62, and rho=0.72, respectively.  These results 
indicate the FFQ and weighed diet record are associated for LCPUFA and individual n-3 fatty 
acid intakes. 
The associations between the FFQ and 3dDR from this study were greater than those 
observed in two other studies conducted with non-pregnant individuals (16, 24).  Tokudome et 
al. (17) examined the relationship of an FFQ and the average of four weighed 7-day diet records 
administered every four months to estimate the fatty acid intake in Japanese female dietitians. 
Significant Pearson’s correlation coefficients of 0.27, 0.32, 0.39 and 0.43 for total n-3, ALA, 
EPA, and DHA intakes, respectively (P<0.05) were observed.  Similarly, Broadfield et al. (26) 
customized a previously validated semi-quantitative FFQ to assess dietary fatty acids in healthy 
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adults (n=31, demographics unspecified) using a weighed diet record as the reference method.  
Spearman’s correlation coefficients were calculated to determine the relationship between the 
FFQ and weighed diet record for total n-3 (rho=0.23), EPA (rho=0.50) and DHA (rho=0.37) 
(P<0.05).  Significant correlations were also observed between both dietary assessment tools 
for total fat, total SFA, palmitic acid, stearic acid, oleic acid, total n-6, and linoleic acid.  These 
results support our findings that an FFQ specifically designed to measure n-3 fatty acid intake is 
associated with data obtained from a weighed 3dDR.  
During the present study over half of the subjects reported consuming DHA on the 3dDR 
and FFQ within the same groups of intake (<70 mg DHA/day, 70-199 mg DHA/day, and ≥200 
mg DHA/ day).  These findings are similar to those reported by McNaughton et al. (27) who 
reported classifying  42% individuals in the same quintiles and by Sullivan et al. (19) who 
reported classifying 49% of subjects into the same quartile when intakes of n-3 LCPUFAs were 
estimated using the FFQ and  weighed diet record.  The smaller level of data stratification used 
in the present study is an obvious difference between this study and those conducted by 
McNaughton et al. and Sullivan et al.  The groups defined during this study add clinical 
relevance to the estimated intakes.    For example, by using these defined groups we were able 
to indicate that both the FFQ and 3dDR estimated that 52 individuals were not meeting the 
suggested recommendation of at least 200 mg DHA/ day during the 2nd and 3rd trimester of 
pregnancy.   Additionally, 27 individuals were found to be consuming at least 200 mg/DHA day 
as estimated by the FFQ and weighed 3dDR.  It is also important to note the FFQ was able to 
estimate DHA intake for 59 subjects that did not report consuming DHA on their 3dDR.   For 
example, 13 individuals reported consuming <70 mg DHA/day on the 3dDR and ≥200 mg 
DHA/day on the FFQ.  This discrepancy between estimated intakes may be a result of collecting 
the 3dDR on non-consumption days.     These findings indicate the FFQ is associated with the 
3dDR and it may be better at detecting episodically consumed nutrients like DHA overtime. 
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The agreement between the FFQ and 3dDR in this study were comparable with results 
of previous studies in non-pregnant individuals.  We conclude our FFQ designed to measure 
specific fatty acids is an improvement over previously tested tools which only estimated dietary 
intake of total fat in pregnant women.  Furthermore, the results of this study indicate this FFQ, 
by itself, would be an appropriate tool to estimate an individual‘s total n-3, ALA, EPA, and DHA 
intake within the clinical and research setting if the diet data collection and analysis protocols we 
established are followed.   In conclusion, the semi-quantitative FFQ is capable of estimating 
intake of total n-3, ALA, EPA and DHA and is associated with the weighed 3dDR.      
  
49 
 
References 
1. Makrides M.  Is there a dietary requirement for DHA in pregnancy?  Prostaglandins 
Leukot Essent Fatty Acids.  2009;81:171-174. 
 
2. Villa PM, Laivuori H, Kajantie E, Kaaja R.  Free fatty acid profiles in preeclampsia.  
Prostaglandins Leukot Essent Fatty Acids.  2009;81(1):17-21. 
 
3. McKoy SJB,Beal JM, Miller Shipman SB, Payton ME, Watson GH. Risk factors for 
postpartum depression: a retrospective investigation at 4-weeks postnatal and a review 
of the literature. J Am Osteopath Assoc. 2006;106(4):193-198.  
 
4. Reese AM, Austin MP, Owen C, Parker G.  Omega-3 deficiency associated with 
perinatal depression: case control study. Psychiatry Res. 2009;166(2):254-259. 
 
5. De Vriese SR, Christophe AB, Maes M, Lowered serum n-3 polyunsaturated fatty acid 
(PUFA) levels predict the occurrence of postpartum depression: further evidence that 
lowered n-PUFAs are related to major depression. Life Sci. 2003;73:3181–3187. 
 
6. Innis SM. Dietary (n-3) fatty acids and brain development. J Nutr. 2007;137:855-859. 
 
7. Innis SM. Perinatal biochemistry and physiology of long-chain polyunsaturated fatty 
acids. J Pediatr. 2003;(suppl)143:S1-S8. 
 
8. Innis SM. Essential fatty acid transfer and fetal development. Placenta. 
2005;26(suppl):S70-S75. 
 
9. Innis SM. Fatty acids and early human development. Early Hum Dev. 2007;83:761-766. 
 
10. Institute of Medicine (U.S.). Panel on Macronutrients., Institute of Medicine (U.S.). 
Standing Committee on the Scientific Evaluation of Dietary Reference Intakes. Dietary 
reference intakes for energy, carbohydrate, fiber, fat, fatty acids, cholesterol, protein, 
and amino acids DRI dietary reference intakes for energy. Washington, D.C.: National 
Academies Press; 2005. 
 
11. Koletzko B, Cetin I, Brenna JT for the Perinatal Lipid Intake Working Group.  Dietary fat 
intakes for pregnant and lactating women. Br J Nutr. 2007;98(5):873-877. 
 
12. The importance of DHA during pregnancy and nursing. Martek website. 2010.  Available 
at http://www.martek.com/Healthcare-Professionals/Clinical-Research/Maternal-
Health/tabid/134/Default.aspx  Accessed on February 1, 2010. 
 
13. Brenna JT, Lapillonne A.  Background paper on fatty acid requirements during 
pregnancy and lactation.  Ann Nutr Metab. 2009;55:97-122. 
50 
 
 
14. Bingham SA, Nelson M.  Assessment of food composition and nutrient intake.  In:  
Margetts BM, Nelson M eds.   Design Concept in Nutritional Epidemiology. 3rd ed. 
Oxford, NY: Oxford University Press; 2000:153-191. 
 
15. Meyer BJ, Mann NJ, Lewis JL, Milligan GC, Sinclair AJ, Howe PRC.  Dietary intakes and 
food sources of omega-6 and omega-3 polyunsaturated fatty acids. Lipids. 2003;38:391-
398. 
 
16. Taren D, Dwyer J, Freedman L, Solomons NW.  Dietary assessment methods:  where 
do we go from here?  Public Health Nutr.  2002;5:1001-1003. 
 
17. Tokudome S, Imaeda N, Tokudome Y, Fujiwara N, Nagaya T, Sato J, Kuriki K, Ikeda M, 
Maki S. Relative validity of a semi-quantitative food frequency questionnaire versus 28 
day weighed diet records in Japanese female dietitians. Eur J Clin Nutr. 2001;55(9):735-
742. 
 
18. Segovia-Siapco G, Singh P, Jaceldo-Siegl K, Sabate J.  Validation of a food-frequency 
questionnaire for measurement of nutrient intake in a dietary intake study.  Public Health 
Nutr.  2005;10(2)177-184. 
 
19. Sullivan B, Brown J, Williams P, Meyer B. Dietary validation of a new Australian food 
questionnaire that estimates long chain n-3 polyunsaturated fatty acids. Br J Nutr. 
2008;99:660-666. 
 
20. Broadfield E, McKeever T, Fogarty A, Britton J.  Measuring dietary fatty acid intake:  
validation of a food-frequency questionnaire against 7 d weighed records.  Br J Nutr. 
2003;90:215-220. 
 
21. Knutsen SF, Fraser GE, Beeson WL, Lindsted KL, Shavlik DJ.  Comparison of adipose 
tissue fatty acids with dietary fatty acids measured by 24-hour recall and food frequency 
in Black and White Adventists:  the Adventist Health Study.  Ann Epidemiol. 
2003;13:119-127. 
 
22. Cade J, Thompson R, Burley V, Warm D.  Development, validation and utilisation of 
food-frequency questionnaires-a review.  Public Health Nutr. 2002;5(4):567-587. 
 
23. Cade J, Burley V, Warm D, Thompson R, Margetts B.  Food-frequency questionnaires: a 
review of their design, validation and utilisation.  Nutr Res Rev. 2004;17:5-22. 
 
24. Biro G, Hulshof K, Ovesen L, Cruz J.  Selection of methodology to assess food intake. 
Eur J Clin Nutr.  2002;56(suppl):S25-S32. 
 
51 
 
25. Knutsen SF, Fraser GE, Beeson WL, Lindsted KL, Shavlik DJ.  Comparison of adipose 
tissue fatty acids with dietary fatty acids measured by 24-hour recall and food frequency 
in Black and White Adventists:  the Adventist Health Study.  Ann Epidemiol. 
2003;13:119-127. 
 
26. USDA Nutrient Database for Standard Reference.  USDA website. Available 
from: http://www.nal.usda.gov/fnic/foodcomp/Data/SR18/sr18.html.  Accessed on May 1, 
2010. 
 
27. McNaughton S, Hughes M, Marks G. Validation of a FFQ to estimate the intake of PUFA 
using plasma phospholipid fatty acids and weighed food records.  Br J Nutr. 
2007;97:561-568. 
 
28. Rumpler WV, Krame M, Rhodes DG, Moshfegh AJ, Paul DR.  Identifying sources of 
reporting error using measure food intake.  Eur J Clin Nutr. 2008;62:544-552. 
 
29. Poslusna K, Ruprich J, de Vries JHM, Jakubikova M, van’t Veer P.  Misreporting or 
energy and micronutrient intake estimated by food records and 24 hour recalls, control 
and adjustment methods in practice.  Brit j of Nutr.  2009;101(suppl 2):S73-S85. 
 
30. Emmet P.  Assessing diet in longitudinal birth cohort studies.  Paediactr Perinat Epidem. 
2009;23(suppl1):S154-S173. 
 
31. van Eijsden M, Hornstra G, van der Wal MF, Bonsel GJ.  Ethnic differences in early 
pregnancy maternal n-3 and n-6 fatty acid analysis.  Brit J Nutr. 2009;101:1761-1768. 
 
32. Erkkola M, Karppinen M, Javanainen J, Rasanen L, Knip M, Virtanen SM.  Validity and 
reproducibility of a food frequency questionnaire for pregnant finnish women. Am J 
Epidemiol.  2001;154(5):466-476.   
 
33. Tarasuk VS, Brooke A.  Interpreting epidemiologic studies of diet-disease relationship.  J  
Nutr.  1997;127(9):1847-1852. 
 
 
  
52 
 
 
Table 1.  Median (5th-95th percentiles) total and individual n-3  fatty acid dietary intakes estimated via 
the food frequency questionnaire (FFQ) and weighed 3-day diet record (3dDR) in pregnant women 
during the 2nd and 3rd trimester (n=136). 
  
     Semi-quantitative FFQ (g/d)                       Weighed 3dDR (g/d) 
Dietary fatty acid a Median (5th-95th percentile) Median (5th-95th percentile) 
total n-3  1.935 (0.746-5.358) 1.609 (0.595-4.001) 
ALA 1.542 (0.650-4.081) 1.481 (0.568-3.396) 
EPA 0.023 (0.002-0.183) 0.009 (0.000-0.248) 
DPA 0.131 (0.004-1.555) 0.006 (0.000-0.134) 
DHA 0.056 (0.007-0.371) 0.028 (0.001-0.452) 
 
a Alpha-linolenic acid (ALA), eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA), and docosahexaenoic acid 
(DHA) 
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Table 2.  Agreement between the 3dDR and FFQ for different levels of estimated mean 
docosahexaenoic acid (DHA) intake (n=136). 
Group Agreement 
between groups 
Disagreement 
between groups 
Percent Agreement 
<0.070 g DHA/day  46ª 32 58% 
0.070-0.199 g DHA/day  6 11  35% 
≥0.200 g DHA/day  27 14  66% 
ª Number of subjects. 
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Figure 1.  Spearman’s correlation coefficients without outliers for mean estimated intakes of 
total n-3 (n=135), alpha linolenic acid (ALA) (n=135), eicosapentaenoic acid (EPA) (n=134), 
docosapentaenoic acid (DPA) (n=134), and docosahexaenoic acid (DHA) (n=134) collected via 
the food frequency questionnaire (FFQ) and weighed 3-day diet record (3dDR). 
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CHAPTER 5:  Validation of a semi-quantitative food frequency questionnaire with blood 
biomarkers in pregnant women for total and individual n-3 fatty acids 
              A paper to be submitted to the Journal of the American Dietetic Association 
Rebecca Filipowicz, Christina Campbell  
Abstract 
Background   
Omega 3 (n-3) fatty acids are important structural components of cell membranes. 
Previous clinical research shows DHA intake during pregnancy supports positive fetal visual 
acuity and motor skills. Despite the interest in prenatal n-3 fatty acid intake, limited studies have 
examined the association between total and individual intakes measured by a food frequency 
questionnaire (FFQ) and plasma or red blood cell (RBC) n-3 fatty acid status during pregnancy. 
Objective   
We examined the relationship between the semi-quantitative FFQ and weighed 3-day 
diet record (3dDR) intakes with plasma phospholipids (PLs) and RBC esterified fatty acids 
(phoshatidylethanolamine (PE) and phosphatidylcholine (PC)) composition for total and 
individual n-3 fatty acids (alpha-linoleic acid (ALA) and the n-3 fatty acids eicosapentaenoic acid 
(EPA), docosapentaenoic acid (DPA), and docosahexaenoic acid (DHA))  in pregnant women 
from two non-coastal communities. 
Design 
 Dietary n-3 fatty acid intake was estimated using an FFQ and weighed 3dDR and 
associated with blood biomarkers in a subset of 64 pregnant women (25-31 weeks of gestation) 
from ongoing observational.  The FFQ was previously validated with the 3dDR for total n-3, 
ALA, EPA, and DHA intake.  Spearman’s correlation coefficients were used to identify the 
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associations between estimated dietary intake of total and individual n-3 fatty acids from the 
FFQ and 3dDR and fatty acid compositions of plasma PLs and RBC PE and PC.   
Results 
The results of this study indicate the estimated intakes of total and individual n-3 
fatty acids from a semi-quantitative FFQ are more associated with blood biomarkers than 
estimated intakes of total and individual n-3 fatty acids from a weighed 3dDR in pregnant 
women living in non-coastal communities.  Spearman’s correlations coefficients between the 
intakes estimated from the FFQ and plasma PL for EPA and DHA (rho=0.33 and rho=0.46, 
respectively), and RBC PE and PC for total n-3 (rho=0.39 and rho=0.27, respectively), EPA, 
(rho=0.45 and rho=0.36, respectively) and DHA (rho=0.56 and rho=0.47, respectively) were 
significant.   DHA intake obtained from the 3dDR exhibited a significant positive association for 
plasma PL (rho=0.34) and RBC PE and PC (rho=0.40 and rho=0.42, respectively).  The 3dDR 
DPA estimated intake was not associated with blood biomarkers.   
Conclusion   
 The estimated intakes of total and individual n-3 fatty acids from a semi-quantitative FFQ 
are more strongly associated with blood biomarkers than estimated intakes of total and 
individual n-3 fatty acids from a weighed 3dDR in pregnant women living from non-coastal 
communities.  In conclusion, the semi quantitative FFQ is a more appropriate tool to estimate 
total and individual n-3 fatty acid intakes in clinical and research settings.       
Introduction      
The essential omega 3 (n-3) fatty acid alpha-linoleic acid (ALA) and the n-3 fatty acids 
eicosapentaeneoic acid (EPA), docosapentaenoic acid (DPA), and docosahexaenoic acid 
(DHA) are important structural components of cell membranes (1).  During pregnancy a steady 
supply of n-3 fatty acids is required to support positive fetal development (1-4) and maternal 
health (5-9).  Over the past decade, extensive clinical research has focused on the role of DHA 
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during pregnancy because it is incorporated into fetal brain grey matter and retina cell 
membranes more than any other n-3 fatty acid (4).  The Adequate Intake (AI) for ALA (1.4 
g/day) is routinely met in the American diet through the consumption of foods containing 
soybean and canola oil (10).  The consumption of preformed EPA, n-3 DPA, and DHA is 
recommended as a result of the low conversion rate of ALA to EPA, n-3 DPA, and DHA during 
pregnancy (11). Maternal intake of at least 200 mg DHA per day throughout gestation is 
recommended to support a healthy pregnancy, to prevent maternal depletion of DHA and to 
meet the increased fetal demands of 67 mg DHA per day during the third trimester, a period of 
rapid fetal growth (12-14).  At this time there are no dietary recommendations for EPA and DPA 
intake during pregnancy.  Dietary sources of DHA are fatty fish, seafood, meat, and eggs (14); 
EPA and DPA are routinely found in the same dietary sources as DHA (15).  Fortified foods and 
supplements are also consumable sources of ALA, EPA and DHA.         
As a result of the growing body of research which focuses on the affects of n-3 fatty 
acids on maternal and fetal health, several studies have determined the association between 
dietary intake of n-3 fatty acids and n-3 fatty acids status (biological measurement/level) during 
pregnancy (16-19).  However, no known studies have the primary objective of validating the use 
of a food frequency questionnaire (FFQ) to estimate total and individual n-3 fatty acids with a 
biological reference measurement in pregnant women from non-coastal communities.  Dietary 
assessment tools have been previously validated with biological measurements because they 
are objective and do not rely on memory or compliance of the participant (20-23).  Possible 
biological measurements that can be used to validate an FFQ include isotopes, adipose biopsy, 
and blood.  Isotopes are highly accurate and do not require the same special handling as 
adipose and blood samples (21).  However, the use of isotopes as a biological reference 
measure in pregnant women is inappropriate at this time because the physiological influences of 
isotopes are not fully understood.  Adipose tissue has also been used to validate an FFQ 
designed to assess dietary intake and considered by some researchers be highly reflective of 
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fatty acid status (22).  The half life (t1/2) of adipose tissue is between 1 and 2 years and does not 
correspond with the length of pregnancy (10 months) (22).  Additionally collecting adipose 
biopsies may be perceived as too invasive and diminish participation levels.  Therefore, adipose 
is not a favorable biological reference method for the determining the association of dietary n-3 
fatty acid intake and status in pregnant women.    
Plasma phosopholipids (PL) and red blood cell (RBC) phoshatidylethanolamine (PE) and 
phosphatidylcholine (PC) fatty acid compositions have been used to determine fatty acid status 
in pregnant women because they are easy to collect and have low levels of risk for the mothers 
and their fetus (16-17).  Plasma fatty acids fractions may be useful biological measurements to 
determine the association between short term dietary intake of total and individual n-3 fatty 
acids maternal fatty acid status because it has a t1/2 of 10 days (22).  Additionally, RBC fatty 
acid fractions may be a useful biological measurement to determine the association between 
long term dietary intake of total and individual n-3 fatty acids maternal fatty acid status because 
it has a t1/2 of 30 days (22).  A known disadvantage of blood biomarkers is that they do not 
reflect true absolute intake because of the affects of digestion, absorption, uptake, utilization, 
metabolism, excretion, homeostatic mechanisms, and error associated by the biochemical 
measures themselves (21). Both plasma phospholipids (PL) and red blood cells (RBC) PE and 
PC have exhibited positive correlations with n-3 fatty acids estimated from an FFQ in pregnant 
(16-17) and non-pregnant individuals (24).   
We have developed a semi-quantitative FFQ that is positively associated with a weighed 
3-day diet record (3dDR) for estimated intakes of total n-3, ALA, EPA, and DHA in women 
(n=136) during the 2nd and 3rd trimester of pregnancy residing in non-coastal communities (data 
unpublished).  The FFQ also estimated intake of ALA, EPA, and DHA from fortified foods and 
supplements.  The usefulness of this FFQ in clinical and research settings would be further 
supported if the estimated intakes of total and individual n-3 fatty acids from the FFQ and 
60 
 
weighed 3-day diet record were validated with total and individual n-3 fatty acid status during 
pregnancy.     
The aims of this study were: 1) to examine the relationship between total n-3, ALA, EPA, 
DPA, and DHA estimated intakes from the FFQ and plasma PL, RBC PE and PC; and 2) to 
examine the relationship between total n-3, ALA, EPA, DPA, and DHA estimated intakes from 
the weighed 3dDR and plasma PL, RBC PE and PC in women during the 2nd or 3rd trimester of 
pregnancy residing in two non-coastal communities.  It was hypothesized that total and 
individual n-3 fatty acid intakes estimated from FFQ would show strong correlations with RBC 
PE and PC total and individual n-3 fatty acid compositions and that total and individual n-3 fatty 
acid intakes estimated from weighed 3dDR would show strong correlations with plasma PL total 
and individual n-3 fatty acid compositions       
Methods 
A subset of participants (n=64) from an ongoing prospective observational study was 
used for the comparison of the FFQ and 3dDR with plasma and RBC fatty acid biomarkers. 
Participants from Bozeman, Montana and Ames, Iowa were included in the convenience sample 
because they were between 25-31 weeks pregnant, pregnant with one baby, between the ages 
of 18-45, non-smokers, and had no previous history of chronic disease (type 2 diabetes, 
hypertension, heart disease, chronic renal disease).  Informed consent was obtained when the 
subject signed a consent form approved by the Montana State University Institutional Review 
Board (IRB) or by the Iowa State University IRB according to the location they participated in the 
study.  Age, income, highest grade of education completed, number of parities, pre-pregnancy 
weight, and marital status were documented.  Self-reported height was documented in feet and 
inches.  A portable Sunbeam analog scale (Boca Raton, FL) was used to record weight to the 
nearest tenth of a pound.   
Dietary Assessment 
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Total and individual n-3 fatty acid intake was estimated using a semi-quantitative FFQ 
and 3dDR over a 7 day period.  Subjects were randomly assigned to one of two orders (FFQ 
prior to weighed 3dDR or vice versa) to avoid bias. The 107-food item semi-quantitative FFQ 
measured the twelve categories of food:  milk products, yogurt/ice cream, fats and oils, 
poultry/meat, fish, eggs, vegetables, fruit, snacks, grains, fast food, and supplements. Within 
each category trained interviewers thoroughly inquired about intake of foods including those 
fortified with n-3 fatty acids, different cuts of meat and types of fish, cooking and spreading fats, 
eggs, and supplements containing EPA and DHA.  Frequency was measured using the 
following categories: 1-4 times per day, 1-7 times per week or 1-3 times per month.  Portion size 
was estimated using food models and measuring cups.  Indirect inquiry was used to estimate 
consumption of EPA and DHA supplements and n-3 fatty acid fortified foods during the FFQ 
interview to avoid influencing the subjects from seeking out and consuming fortified foods and 
supplements.  The FFQ interview took approximately 45 minutes to complete.  Participants 
received detailed instructions on how to complete a weighed 3dDR (two week days and one 
weekend day diet, which were not required to be consecutive) using a Cuisinart SA-110A scale 
(Cuisinart, East Windsor, NJ).  Once the subject returned the weighed 3dDR, a member of the 
research staff reviewed the dietary log with the subject to ensure complete record taking and to 
clarify any discrepancies that may exist.   
Diet Analysis 
 Diet data was analyzed using Nutritionist Pro Version 4.2.2 (2009) dietary intake 
analysis software (Axxya Systems; Stafford, TX).   The dietary intake analysis software was 
modified by the first author to include fortified foods and supplements.  The FFQ and 3dDR for 
each subject was analyzed by the same trained research staff to ensure consistent food 
selections between records.  Additionally, USDA Nutrient Database for Standard Reference 
food choices was chosen over brand name foods because they contained more complete 
dietary information for dietary fatty acids. Dietary intake of DPA was analyzed using the USDA 
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Nutrient Database for Standard Reference (25).  Dietary analysis output was further reviewed 
by the first author to ensure the food with most complete fat composition was selected and to 
ensure that the DHA and/or DHA + EPA supplements choices matched between the FFQ and 
weighed diet record.  The FFQ was previously shown to be significantly associated with a 
weighed 3dDR for total n-3 (rho=0.98, P<0.01), ALA (rho=0.27, P<0.01), EPA (r=0.56, P<0.01) 
and DHA (r=0.66, P<0.01) (unpublished data).     
Blood collection 
A fasted (no food or calorie containing beverages for at least eight hours) maternal 
venous blood sample was collected in an EDTA vacutainer (Becton Dickenson, Franklin Lakes, 
NJ) to coincide with dietary data collection.  Vacutainers containing blood were placed on ice 
immediately after collection to maintain the integrity of the sample. Once the blood samples 
were returned to the MSU Nutrition Research Lab or the ISU campus they were centrifuged at 
2000 g for 10 minutes at 4 degrees C to separate the plasma from the RBC.   Plasma was 
stored at -80 degrees C.     The remaining RBCs were washed with saline/EDTA (9 g/Liter 
sodium chloride and 1.14 g/Liter sodium EDTA in deionized water) and centrifuged at 2000g for 
10 min at 4 degrees C.  The buffy layer was removed and the wash step was repeated one 
more time to ensure all plasma had been washed away from the RBC.  The RBCs were also 
stored at -80 degrees C.      
 Fatty acid analysis 
Plasma lipids were extracted using a modified Folch (26) extraction procedure using 2 
parts sample in saline, 3 parts methanol and 6 parts chloroform.  After vortexing and 
centrifugation at 2500 g for 10 minutes, the lower organic phase was collected.  The aqueous 
phase was washed with additional chloroform and again the organic phase was collected, 
pooled with the first organic phase then dried under nitrogen to obtain a total lipid extract. 
Red blood cell lipid classes were separated using TLC.  Lipid fractions were recovered 
and converted to their respective methyl esters by gas chromatography with flame ionization 
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using an Agilent 6850 gas chromatogram (Agilent Technologies Inc., Santa Clara, CA) with an 
Agilent HP-88 capillary column (30 m x 0.35 mm internal diameter x 20-µ film thickness).  
Agilent Chemstation software (Agilent Technologies Inc., Santa Clara, CA) was used to quantify 
the fatty acid peaks as a percent weight (g/100 g fatty acid) of each fatty acid based on the area 
under the curve.   
Statistical Analysis   
Mean and median values were determined for total and individual n-3 fatty acid dietary 
intake estimated by the FFQ and 3dDR and plasma and RBC fatty acid compositions.  A 
Kolmogorov–Smirnov (K-S) test was used to test for a normal distribution of n-3 fatty acid 
dietary intake data from the FFQ and 3dDR and the n-3 fatty acid composition measured via 
plasma PL and RBC PE and PC.  Spearman’s correlation coefficients determined the 
relationship between the total and individual n-3 fatty acid intakes from the FFQ and 3dDR and 
the plasma and RBC fatty acid composition.  Diet and blood associations for EPA and DHA 
were also examined using Spearman’s correlation coefficient for non-supplement and 
supplement users.  Data were analyzed using Predictive Analytical Software (PASW) 18.0.0 
(SPSS Inc, Chicago, IL).  Statistical significance was set at P<0.05.     
Results 
Subject Characteristics 
Dietary data was analyzed as one group because age, gestation length, and pre-
pregnancy BMI were previously determined to not differ significantly betweens subjects from MT 
and IA (unpublished data).  Sixty-four women completed the study; subject characteristics are 
provided in Table 1.  One subject was treated as an outlier because her DHA intake collected 
via the FFQ was ± 2 standard deviations (SD) from the mean. No other outliers existed for total 
n-3, ALA, EPA, and n-3 DPA intakes; therefore data from 63 women were included in the final 
analysis. 
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Total n-3 fatty acid intake represents the sum of all ALA, EPA, DPA, and DHA fatty acids 
estimated in the diet.  A K-S tested indicated non-normal distributions for total n-3, ALA, EPA, 
DPA, and DHA intakes estimated by the FFQ and 3dDR intakes (P<0.01). Table 2 presents the 
median and 5th-95th percentile of total and individual n-3 fatty acid intake as measured by 3dDR 
and FFQ for all subjects (n=63), supplement users (n=19), and non-supplement users (n=44). 
The FFQ estimated greater mean intakes in all subjects than the weighed 3dDR for total n-3 
fatty acid (2.082 ± 1.435 g/d vs. 1.773 ± 1.158 g/d, respectively), ALA (1.640 ± 1.221 g/d vs. 
1.501 ± 0.949 g/d, respectively), EPA (0.094 ± 0.173 g/d vs. 0.089 ± 0.174 g/d, respectively), 
and DPA (0.220 ± 0.490 g/d vs. 0.022 ± 0.040 g/d, respectively).  In all subjects, estimated 
mean intake of DHA collected by the FFQ was less than the estimated mean intake of DHA 
collected by the weighed 3dDR (0.144 ± 0.160 g/d vs. 0.161 ± 0.232 g/d, respectively).   
Supplement user’s estimated mean EPA intake from the FFQ (0.188 ± 0.170 g/d) and the 3dDR 
(0.220 ± 0.258 g/d) was greater than the non-supplement users estimated mean EPA intake 
from the FFQ (0.030 ± 0.044 g/d) and the 3dDR (0.031 ± 0.064 g/d).  The supplement users 
estimated mean DHA intake reported by the FFQ and 3dDR (0.311 ± 0.159 g/d and 0.399 ± 
0.270, respectively) was also greater than non-supplement users estimated mean DHA intake 
reported by the FFQ and 3dDR (0.070 ± 0.095 g/d and 0.057 ± 0.101 g/d, respectively).     
  Total n-3 fatty acids represent the sum of all ALA, EPA, DPA, and DHA fatty acids 
detected in the blood.  A K-S test indicated non-normal distributions for total n-3, ALA, EPA, 
DPA, and DHA status for plasma PL and RBC PE and PC (P<0.01). The median and 5th-95th 
percentile are shown for all subjects, supplement users, and non-supplement users in Table 2.  
Mean  ± SD plasma PL for all subjects (n=63) for total n-3, ALA, EPA, DPA, and DHA was 5.668 
± 1.358 g/100 g, 0.279 ± 0.081 g/100 g, 0.399 ± 0.273 g/100 g, 0.713 ± 0.154 g/100 g, and 
4.278 ± 1.060 g/100 g, respectively.   Mean (±SD) fatty acid compositions measured in the RBC 
PC were less than RBC PE in all subjects for total n-3 (2.595 ± 0.671 g/100 g vs. 6.350 ± 1.547 
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g/100 g), EPA (0.217 ± 0.139 g/100 g vs. 0.275 ± 0.141 g/100 g), DPA (0.373 ± 0.087 g/100 g 
vs. 1.935 ± 0.468 g/100 g), and DHA (1.761 ± 0.520 g/100 g vs. 3.969 ± 1.093 g/100 g). Mean 
(±SD) fatty acid compositions measured in the RBC PC were greater than RBC PE in ALA 
(0.243 ± 0.069 g/100 g vs. 0.167 ± 0.069 g/100 g).  The supplement users EPA composition for 
plasma PL (0.399 ± 0.273 g/100 g), RBC PE (0.275 ± 0.141 g/100 g), and RBC PC (0.399 ± 
0.273 g/100 g) was greater than non-supplement users EPA composition for plasma PL (0.307 
± 0.136 g/100 g), RBC PE (0.233 ± 0.009 g/100 g), and RBC PC (0.166 ± 0.064 g/100 g).  The 
supplement users had higher DHA composition than non-supplement users in plasma PL (4.983 
± 1.073 g/100 g vs. 3.937 ± 0.908 g/100 g), RBC PE (4.577 ± 1.360 g/100 g vs. 3.706 ± 0.846 
g/100 g), and RBC PC (2.131 ± 0.516 g/100 g vs. 1.601 ± 0.438 g/100 g).   
Spearman’s correlation coefficients were calculated to illustrate the association between 
diet data collected from the 3dDR and FFQ and the plasma PL and RBC PC and PE fatty acid 
compositions for all subjects, supplement users, and non-supplement users (Table 3).  Bivariate 
plots (Figure 1 A-C) showed that as individual intakes of DHA estimated from the FFQ 
increased, individual DHA fatty acid compositions measured in plasma PL and RBC PE and PC 
also increased.  Additionally, a smaller degree of heteroscedasticity was observed in the 
bivariate plots for estimated DHA intake from the FFQ vs. plasma PL, RBC PE and PC DHA 
(Figure 1:  A-C) compared to the bivariate plots for estimated DHA intake from 3dDR vs. plasma 
PL, RBC PE and PC DHA (Figure 1:  D-F).   
Spearman’s correlation coefficients for supplement users revealed that as estimated 
individual DHA intakes measured by the FFQ increased, DHA composition in plasma PL and 
RBC PC also increased (Table 3).  Estimated individual DHA intake measured by the 3dDR and 
RBC PC DHA compositions followed a similar pattern for supplement users.  For supplement 
users, estimated DHA intakes from the FFQ were associated with RBC PE.  The FFQ was 
associated with RBC PE for DHA.  No associations were observed between non-supplement 
user’s estimated dietary intakes from the 3dDR and plasma PL, RBC PC for EPA and DHA.  
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Discussion 
The results of this study indicate the estimated intakes of total and individual n-3 fatty 
acids from a semi-quantitative FFQ are more associated with blood biomarkers than estimated 
intakes of total and individual n-3 fatty acids from a weighed 3dDR in pregnant women living in 
non-coastal communities.  The magnitude of correlation coefficients between estimated dietary 
fatty acid intakes and blood fatty acid compositions observed in the present study are similar to 
those previously reported.  
The FFQ-plasma correlations were greater than the correlations between intake from the 
3dDR-plasma correlations for total n-3 fatty acids, EPA and DHA.   In contrast, the 3dDR-
plasma correlations were higher than FFQ-plasma correlations for ALA. Both methods showed 
poor correlations for DPA.  These correlations are similar to those observed by Sun et al. (27) 
between an FFQ and plasma PL for ALA (rho=0.23), EPA (rho=0.21), n-3 DPA (rho= -0.03), and 
DHA (rho=0.48) in non-pregnant females (n=306). Additionally, the results of the present study 
are similar to findings of other studies conducted in pregnant women from coastal communities. 
de Vriese et al. (18) described the relationship between dietary intakes of LCPUFA estimated by 
a previously validated FFQ (17) and LCPUFA compositions in maternal plasma PL  collected at 
birth in pregnant women (n=30) residing near the coast of Belgium.  Significant Pearson’s 
correlations between maternal dietary fatty acid intake and maternal plasma PLs for EPA PL 
(r=0.48) and DHA PL (r=0.52) (P<0.05) were greater than those observed in the present study.  
Similarly, Innis et al. (28) determined the association between dietary estimated intakes of n-3 
fatty acids with plasma PL n-3 fatty acid compositions in pregnant women (n=55) residing 
around Vancouver.  Dietary intake of EPA and DHA estimated by the FFQ were significantly 
related to the compositions of DHA (r = 0.61, P < 0.0001) and EPA (r = 0.55, P < 0.0001) in the 
plasma PL. No significant associations were found for ALA between dietary and plasma PL 
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compositions.  These results support our findings that the estimated intakes of n-3 fatty acids 
from the FFQ are associated with plasma PL n-3 fatty acid composition.    
It is more difficult to discuss the association of estimated intake of n-3 fatty acids with 
RBC PE and PC in relation to previously published works because few studies examine the 
association between intakes of n-3 fatty acids with these specific RBC fatty acid fractions.  More 
often than not authors report total RBC fatty acid compositions.  For example, Parra et al. (29) 
measured the association between dietary intake of n-3 fatty acids and n-3 fatty acid status 
during the third trimester of pregnancy (n=35).  Pearson correlation coefficients between dietary 
intake and RBC were significantly associated for ALA (r=0.32), EPA(r=0.36), and DHA (r=0.35) 
(P≤0.05). A linear regression model demonstrated that RBC ALA and DHA compositions were 
positively related to dietary intake for ALA (r=0.52) and DHA (r=0.30); these results support our 
hypothesis that an FFQ may be a more reliable method than the 3dDR for estimating n-3 
intakes in pregnant women overtime because it is better at documenting episodic intake of 
specific n-3 fatty acids like EPA and DHA.   
The results of the present study are most suitably compared to those reported by 
Friesen et al. (30) when dietary intakes of n-3 fatty acids were compared to RBC PE and PC in 
near-term pregnant women (n=105). Estimated intakes were significantly associated with RBC 
PE (rho=0.31, P<0.001) and RBC PC (rho=0.37, P<0.001) for DHA.  Additionally, estimated 
EPA intakes were positively associated with RBC PE EPA (rho=0.39, P<0.001).  The results 
reported by Friesen et al. are similar to the results of the present study because specific RBC 
fatty acid fraction (PE and PC) were measured and because reported PE fatty acid 
compositions included alkenyl-linked fatty acids.   
The present study differs from previously published studies because EPA and DHA 
supplementation intake was retained in the final analysis.   No correlations were observed 
between EPA intake and blood biomarkers for the supplement user group.  However, a 
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significantly positive correlation was observed between total DHA intake RBC PE and PC in the 
supplement user group.  No association was observed between dietary intake and plasma PL, 
or RBC PE and PC for EPA and DHA in the non-supplement users.  .   
Our study has two limitations.  First, metabolism of n-3 fatty acids during pregnancy is 
dynamic; therefore, compartmentalization of n-3 fatty acids may change throughout pregnancy 
(16).  Additionally, the factors that influence endogenous mobilization of fatty acids during 
pregnancy differ between individuals and should be taken into full consideration.  The second 
limitation of our study is that despite our meticulous collection and analysis of intake, the dietary 
assessment tools used to collect diet data always have some degree of measurement error and 
do not reflect true intake.     
In summary, this study indicates that the estimated intakes of total and individual n-3 
fatty acids obtained from a semi-quantitative FFQ exhibited a stronger association with blood 
biomarkers than estimated intakes of total and individual n-3 fatty acids from a weighed 3dDR in 
pregnant women living in non-coastal communities.  It was observed that the FFQ and RBC PE 
and PC were associated for total n-3 fatty acids, EPA, and DHA.  The dietary intakes of ALA, 
EPA, and DHA estimated by the FFQ were associated with plasma PL.  Dietary intake of DPA 
estimated by the FFQ and DPA blood biomarkers showed poor correlations on all accounts.  
The 3dDR was associated with RBC PE for total n-3 and DHA and with RBC PC for ALA, DPA, 
and DHA.  Finally, the 3dDR and plasma PL were associated for ALA, EPA, and DHA.  The 
more frequent and greater associations observed between the FFQ and blood biomarkers may 
have resulted from the ability of the FFQ to estimate episodic intake of nutrients overtime. In 
conclusion, the semi-quantitative FFQ is an appropriate tool to estimate total and individual n-3 
fatty acid intakes in clinical and research settings.       
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Table 1.  Anthropometrics and Demographics (n=64). 
Characteristic Mean ± SD 
Age (years) 31.0 ± 4.0 
Pre-pregnancy BMI (kg/m2) 25.8 ± 13.5 
Week of Gestation 28.4 ± 1.3 
  n 
Grade Level Completed 
High School 3 
College 34 
Graduate/Professional School 27 
  
Income ($ per year) 
<20,001 12 
30,001-50,000 13 
50,001-75,000 39 
  
Race 
American Indian or Alaska 
Native 1 
Caucasian 63 
  
Marital Status 
Single 1 
Married 63 
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Table 2.  Total and individual omega 3 (n-3) fatty acid dietary intakes from the 3dDR and FFQ and compositions (g/100 g) in red blood cell (RBC) 
phoshatidylethanolamine (PE) and phosphatidylcholine (PC) and plasma phospholipids (PL) of pregnant women.  
 Diet (g/d) Blood (g/100 g fatty acid) 
 Median (5th-95th percentile) Median (5th-95th percentile) 
Fatty Acids b 3dDR  FFQ  RBC PE ª RBC PC  Plasma PL  
All Subjects (N=63) 
     
total n-3 1.467 (0.607-4.724 1.718 (0.720-5.298) 6.129 (3.780-9.376) 2.527 (1.441-3.973) 5.365 (3.980-8.777) 
ALA 1.305 (0.581-3.170) 1.462 (0.531-4.358) 0.184 (0.052-0.292) 0.236 (0.130-0.375) 0.275 (0.137-0.443) 
EPA 0.008 (0.000-0.406) 0.019 (0.002-0.376) 0.230 (0.110-0.560) 0.184 (0.094-0.538) 0.313 (0.179-1.029) 
DPA 0.005 (0.000-0.140) 0.048 (0.002-1.402) 1.881 (1.143-2.850) 0.361 (0.245-0.579) 0.698 (0.450-1.002) 
DHA 0.037 (0.003-0.732) 0.058 (0.008-0.522) 3.790 (2.371-6.121) 1.717 (0.778-2.611) 4.055 (2.987-6.596) 
Supplement user’s (N=19) 
     
EPA 0.185 (0.000-0.699) 0.196 (0.003-0.409) 0.230 (0.110-0.560) 0.184 (0.094-0.538) 0.313 (0.179-1.029) 
DHA 0.235 (0.128-0.890) 0.271 (0.000-0.541) 4.831 (1.959-6.411) 2.231 (0.966-2.825) 4.851 (3.619-6.691) 
Non-supplement user’s (N=44) 
     
EPA 0.007 (0.000-0.186) 0.014 (0.002-0.161) 0.223 (0.104-0.497) 0.161 (0.074-0.267) 0.289 (0.177-0.455) 
DHA 0.024 (0.001-0.217) 0.031 (0.005-0.360) 3.701 (2.379-5.053) 1.589 (0.759-2.438) 3.757 (2.679-6.226) 
ª For the fatty acids in RBC PE, 23.661 ± 3.344 g/100 g were alkenyl linked. 
b alpha-linolenic acid (ALA), eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA), and docosahexaenoic acid (DHA) 
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Table 3.  Relationship between total and individual n-3 dietary fatty acid intakes as estimated by weighed 3 day diet record (3dDR) and semi-
quantitative food frequency questionnaire (FFQ) and total and individual n-3 fatty acid compositions plasma phospholipids (PL), and red blood cell 
(RBC) phoshatidylethanolamine (PE) and phosphatidylcholine (PC). 
Fatty Acids b Spearman’s Correlation Coefficients 
All Subjects (N=63) FFQ vs PL 3dDR vs PL FFQ vs PE 3dDR vs PE FFQ vs PC 3dDR vs PC 
total n-3 0.14**   0.10** 0.39** 0.31*** 0.27*** 0.22*** 
ALA 0.37** 0.34** 0.22** 0.24*** 0.19*** 0.22*** 
EPA 0.33** 0.17** 0.45** -0.02*** 0.36*** 0.16*** 
DPA 0.16** 0.21** -0.01** -0.03*** 0.22*** 0.27*** 
DHA 0.46** 0.34** 0.56** 0.40*** 0.47*** 0.42*** 
Supplement user’s (N=19) 
EPA 0.36** 0.36** 0.23** 0.20)) 0.39*** 0.36*** 
DHA 0.47** 0.31** 0.43** 0.11*** 0.74*** 0.59*** 
Non-supplement user’s (N=44) 
EPA 0.11** -0.07** 0.24** 0.03)) 0.14*** -0.13*** 
DHA 0.21** -0.11** 0.38** 0.08)) 0.20*** 0.07*** 
*Significant at P<0.05; **significant at P<0.01; ***significant at P<0.001. 
b Alpha-linolenic acid (ALA), eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA), and docosahexaenoic acid (DHA).
  
 
Figure 1.  A-C) The relationshi
intakes from the food frequency questionnaire (FFQ) with DHA 
(PL) and red blood cell (RBC) phoshatidylethanolamine (PE) and 
(PC).  D-F) The relationshi
diet record (3dDR) with DHA 
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GENERAL CONCLUSION 
 Omega 3 fatty acids, specifically EPA and DHA, have received a considerable amount of 
attention because of their positive effects during gestation.   Studies have shown an association 
between estimated n-3 intakes during gestation and maternal health.  Additionally, n-3 fatty 
acids, specifically DHA have been shown to support positive visual acuity and motor skills.  The 
semi-quantitative FFQ may be the most suitable dietary assessment tool to estimate the intake 
of episodically consumed n-3 fatty acid intake in pregnant women. 
The FFQ has shown correlations between other dietary reference methods like the 
weighed diet record and 24-hour recall in non-pregnant individuals.  Additionally, a significantly 
positive association has been shown for the FFQ with blood biomarkers (plasma and RBC) 
when fatty acid intake is measured in non-pregnant individuals.  The administration of two 
dietary assessment tools and the assessment of specific blood biomarkers like plasma PL and 
RBC PE and PC provides a more thorough investigation on how well the FFQ is estimating n-3 
fatty acid intake. 
Our dietary data was collected and analyzed through an in-depth process to reduce the 
possibility of systematic bias.  Blood analysis was more complete than in previous published 
works because we reported specific RBC fractions (PE and PC) to provide a more thorough 
status measurement.  Our dietary data showed a significantly, positive correlation between the 
FFQ and 3dDR when EPA and DHA was assessed.  Furthermore, we observed association 
between all dietary data with all blood biomarkers for DHA.  Dietary EPA collected via the FFQ, 
not the 3dDR, was also associated with blood biomarkers. 
In conclusion, the semi-quantitative FFQ is an appropriate dietary assessment tool to 
estimate intake of total n-3, ALA, EPA and DHA and correlates well with the weighed 3dDR and 
blood biomarkers.     Therefore, this FFQ an acceptable method to assess omega -3 fatty acid 
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intake would be a useful dietary assessment tool to use within the clinical and research settings 
in pregnant women
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Appendix A 
Author (yr) Population Statistics  Significant Correlations between FFQ and/or weighed diet record n-3 dietary 
intakes and Blood Biomarkers 
Dietary Fatty Acid 
Assessment Tool 
RBC Plasma 
McNaughton 
et al. (2007) 
N=43 (18 
males and 25 
females) 
Spearman’s 
Correlation, the 
Methods of Triad 
(not reported)  
FFQ 
Total n3 
LCPUFA         
ALA 
EPA 
n-3 DPA                                        
DHA 
 
Weighed Diet Record 
Total n-3 
LCPUFA                
 ALA              
EPA 
n-3 DPA 
DHA 
 
NA 
 
0.21 
0.38 (P<0.05) 
0.00 
0.21 
0.21 
0.32 (P<0.05) 
 
 
0.33 (P<0.05) 
0.44 (P<0.05) 
0.09 
0.22 
0.25 
0.43 (P<0.05) 
Sun et al. 
(2007) 
N=306 
females 
Spearman’s 
Correlation  
(average of 3 
time points) 
FFQ 
ALA 
EPA 
n-3 DPA 
DHA 
 
0.18 
0.38 (P<0.01) 
0.01 
0.56 (P<0.01) 
 
0.23 
0.21 (P<0.01) 
-0.03 
0.48 (P<0.01) 
Sullivan et al. 
(2008)  
N=53 (20 
males and 33 
females) 
Spearman’s 
Correlation   
FFQ 
n-3 
EPA 
DHA 
 
0.50(P<0.001) 
0.54 (P<0.001) 
0.48 (P<0.001) 
 
0.50(P<0.001) 
0.40 (P<0.01) 
0.39 (P<0.01) 
Otto et al. 
(2001) 
N=67pregnant 
women 
Spearman’s 
Correlation   
FFQ Prepregnancy 
DHA  
 
FFQ Wk10 gestation 
LA 
 
0.65 
 
 
0.64 
 
 
0.67 
De Vriese et 
al.  (2002) 
N=30 
pregnant 
women 
Pearson’s 
Correlation 
FFQ 
LA 
ALA 
EPA 
DHA 
EPA + DHA 
Total n-6 
 
NA 
+PL, CE* 
0.53+(P<0.01),0.53*(P<0.01) 
0.48+(P<0.01) 
0.52+(P<0.01) ,0.39*(P<0.05) 
0.53+(P<0.01) 0.44*(P<0.05) 
0.51+(P<0.01) 
Parra et al. 
(2002) 
N=35 
pregnant 
women 
Pearson’s 
Correlation, then 
linear regression 
FFQ 
ALA  
DHA  
 
0.52 (P=0.641) 
0.30 (P=0.045) 
 
NA 
Innis et al. 
(2002) 
N=55 
pregnant 
women 
Pearson’s 
Correlation 
FFQ 
EPA 
DHA 
 
NA 
 
0.55( P<0.0001) 
0.61( P<0.0001) 
  
 
8
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Table 1.  Total and individual n-3 fatty acid dietary intake as estimated by the semi-quantitative food frequency questionnaire 
(FFQ) and weighed 3-day diet record (3dDR) (n=136). 
  
Semi-quantitative FFQ (g/d) Weighed 3dDR (g/d) 
  
Dietary fatty 
acid 
Median 
(5th-95th percentile) 
Mean ± standard 
deviation 
Median 
(5th-95th percentile) 
Mean ± standard 
deviation 
Spearman's 
correlation 
coefficient 
total n-3  1.935 (0.746-5.358) 2.527 ± 2.040 1.609 (0.595-4.001) 2.486 ± 2.067 0.98 *** 
ALA 1.542 (0.650-4.081) 1.932 ± 1.772 1.481 (0.568-3.396) 1.637 ± 0.986 0.28 *** 
EPA 0.023 (0.002-0.183) 0.050 ± 0.070 0.009 (0.000-0.248) 0.047 ± 0.093 0.56 *** 
DPA 0.131 (0.004-1.555) 0.350 ± 0.616 0.006 (0.000-0.134) 0.023 ± 0.045 0.08  
DHA 0.056 (0.007-0.371) 0.095 ± 0.104 0.028 (0.001-0.452) 0.081 ± 0.140 0.66 *** 
App
e
ndix
 B
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Appendix C 
 
Table 1.  Anthropometrics and Demographics (n=64). 
Characteristic Mean±SD 
Age (years) 31±4 
Prepregnancy weight (kg) 65.8±13.5 
Weight (kg) 74.6±13.5 
Height (kg) 167.6±6.7 
Week of Gestation 28.4±1.3 
  n 
Grade Level Completed 
High School 
12 3 
College 
13 3 
14 2 
15 0 
16 29 
Graduate/Professional 
School 
17+ 27 
  
Income ($ per year) 
1-10,000 2 
10,001-20,000 5 
20,001-30,000 5 
30,001-40,000 5 
40,001-50,000 7 
50,001-75,000 14 
75,000+ 26 
  
Race 
American Indian or Alaska 
Native 1 
Caucasian 63 
  
Marital Status 
Single 1 
Married 63 
    
  
 
 
8
8
 
Table 2.  Dietary intake of total and individual n-3 dietary fatty acid intakes as estimated by weighed 3 day diet record (3dDR) and semi-quantitative food 
frequency questionnaire (FFQ) among all subjects (n=63). 
 
3dDR (g/d) FFQ (g/d) 
  Median (5th-95th percentile) Mean ± SD Median (5th-95th percentile) Mean ± SD 
All Subjects (N=63) 
 total n-3 
 
1.467 (0.607-4.724) 
 
1.773 ± 1.158 
 
1.718 (0.720-5.298) 
 
2.082 ± 1.435 
 ALA  1.305 (0.581-3.170) 1.501 ± 0.949 1.462 (0.531-4.358) 1.640 ± 1.221 
EPA  0.008 (0.000-0.406) 0.089 ± 0.174 0.019 (0.002-0.376) 0.094 ± 0.173 
DPA  0.005 (0.000-0.140) 0.022 ± 0.040 0.048 (0.002-1.402) 0.220 ± 0.490 
DHA 0.037 (0.003-0.732) 0.161 ± 0.232 0.058 (0.008-0.522) 0.144 ± 0.160 
Supplement user’s (N=19) 
total EPA 0.185 (0.000-0.699) 0.220 ± 0.258 0.196 (0.003-0.409) 0.188 ± 0.170 
total DHA 0.235 (0.128-0.890) 0.399 ± 0.270 0.271 (0.000-0.541)   0.311 ±  0.159 
Non-supplement user’s 
(N=44) 
EPA 0.007 (0.000-0.186) 0.031 ± 0.064 0.014 (0.002-0.161) 0.030 ± 0.044 
 DHA 0.024 (0.001-0.217) 0.057 ± 0.101 0.031 (0.005-0.360) 0.070 ± 0.095 
b Alpha-linolenic acid (ALA), eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA), and docosahexaenoic acid (DHA).
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Table 3.  Total and individual fatty acid compositions (g/100 g) in red blood cell (RBC) phoshatidylethanolamine (PE) and phosphatidylcholine (PC) and plasma phospholipids (PL) of 
pregnant women (n=63). 
 
PE PC PL 
Median  
(5th-95th percentile) Mean ± SD 
Median 
 (5th-95th percentile) Mean ± SD 
Median  
(5th-95th percentile) Mean ± SD 
All subjects (N=63) 
total n-3 6.129 (3.780-9.376) 6.350 ± 1.547 2.527 (1.441-3.973) 2.595 ± 0.671 5.365 (3.980-8.777) 5.668 ± 1.358 
ALA 0.184 (0.052-0.292) 0.167 ± 0.069 0.236 (0.130-0.375) 0.243 ± 0.069 0.275 (0.137-0.443) 0.279 ± 0.081 
EPA 0.230 (0.110-0.560) 0.275 ± 0.141 0.184 (0.094-0.538) 0.217 ± 0.139 0.313 (0.179-1.029) 0.399 ± 0.273 
DPA 1.881 (1.143-2.850) 1.935 ± 0.468 0.361 (0.245-0.579) 0.373 ± 0.087 0.698 (0.450-1.002) 0.713 ± 0.154 
DHA 3.790 (2.371-6.121) 3.969 ± 1.093 1.717 (0.778-2.611) 1.761 ± 0.520 4.055 (2.987-6.596) 4.278 ± 1.060 
Supplement 
user’s (N=19) 
EPA 0.230 (0.110-0.560) 0.275 ± 0.141 0.184 (0.094-0.538) 0.217 ± 0.139 0.313 (0.179-1.029) 0.399 ± 0.273 
DHA 4.831 (1.959-6.411) 4.577. ± 1.360 2.231 (0.966-2.825) 2.131 ± 0.516 4.851 (3.619-6.691) 4.983 ± 1.073 
Non-supplement 
user’s (N=44) 
EPA 0.223 (0.104-0.497) 0.233 ± 0.009 0.161 (0.074-0.267) 0.166 ± 0.064 0.289 (0.177-0.455) 0.307 ± 0.136 
DHA 3.701 (2.379-5.053) 3.706 ± 0.846 1.589 (0.759-2.438) 1.601 ± 0.438 3.757 (2.679-6.226) 3.973 ± 0.908 
b Alpha-linolenic acid (ALA), eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA), and docosahexaenoic acid (DHA) 
